



HU000030208T2

(19) **HU**(11) Lajstromszám: **E 030 208**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 10 790825**(22) A bejelentés napja: **2010. 12. 10.**(51) Int. Cl.: **A01K 670/27** (2006.01)**C12N 15/85** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20100790825

(86) A nemzetközi (PCT) bejelentési szám:

PCT/US 10/059845

(97) Az európai bejelentés közzétételi adatai:

EP 2509409 A1 **2011. 06. 16.**

(87) A nemzetközi közzétételi szám:

WO 11072204

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2509409 B1 **2016. 07. 27.**

(30) Elsőbbségi adatok:

285250 P**2009. 12. 10.****US**

(73) Jogosult(ak):

**Regeneron Pharmaceuticals, Inc., Tarrytown,
NY 10591 (US)**

(72) Feltaláló(k):

MACDONALD, Lynn, White PlainsNY 10605 (US)**STEVENS, Sean, San FranciscoCA 94158 (US)****MURPHY, Andrew, J., Croton-on-HudsonNY 10520 (US)**

(74) Képviselő:

**PINTZ ÉS TÁRSAI Szabadalmi, Védjegy és
Jogi Iroda Kft., Budapest**

(54)

Nehézláncú antitesteket termelő egerek

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 509 409 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
27.07.2016 Bulletin 2016/30

(21) Application number: **10790825.3**

(22) Date of filing: **10.12.2010**

(51) Int Cl.:
A01K 67/027 (2006.01) C12N 15/85 (2006.01)

(86) International application number:
PCT/US2010/059845

(87) International publication number:
WO 2011/072204 (16.06.2011 Gazette 2011/24)

(54) **MICE THAT MAKE HEAVY CHAIN ANTIBODIES**

MÄUSE DIE SCHWERE-KETTE ANTIKÖRPER PRODUZIEREN

SOURIS QUI PRODUISENT ANTICORPS A CHAÎNE LOURDE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **10.12.2009 US 285250 P**

(43) Date of publication of application:
17.10.2012 Bulletin 2012/42

(60) Divisional application:
15177538.4 / 2 954 779

(73) Proprietor: **Regeneron Pharmaceuticals, Inc.**
Tarrytown, NY 10591 (US)

(72) Inventors:
• **MACDONALD, Lynn**
White Plains
NY 10605 (US)
• **STEVENS, Sean**
San Francisco
CA 94158 (US)
• **MURPHY, Andrew, J.**
Croton-on-hudson
NY 10520 (US)

(74) Representative: **Power, David**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:

- **JANSSENS RICK ET AL: "Generation of heavy-chain-only antibodies in mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 103, no. 41, 10 October 2006 (2006-10-10), pages 15130-15135, XP002494537 ISSN: 0027-8424 DOI: DOI:10.1073/PNAS.0601108103**
- **RIECHMANN L ET AL: "Single domain antibodies: comparison of camel VH and camelised human VH domains" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 25-38, XP004187632 ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL ISSN: 0022-1759 DOI: 10.1016/S0022-1759(99)00138-6**
- **BRÜGGEMANN MARIANNE ET AL: "Heavy-chain-only antibody expression and B-cell development in the mouse" CRITICAL REVIEWS IN IMMUNOLOGY, vol. 26, no. 5, 1 January 2006 (2006-01-01), pages 377-390, XP009113356 CRC PRESS, INC ISSN: 1040-8401**
- **HENDERSHOT L ET AL: "ASSEMBLY AND SECRETION OF HEAVY CHAINS THAT DO NOT ASSOCIATE POSTTRANSLATIONALLY WITH IMMUNOGLOBULIN HEAVY CHAIN-BINDING PROTEIN" JOURNAL OF CELL BIOLOGY, vol. 104, no. 3, 1987, pages 761-767, XP002622526 ISSN: 0021-9525**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 509 409 B1

Description**FIELD OF INVENTION**

[0001] The field of invention is genetically modified mice that make heavy chain antibodies, in particular genetically modified mice that comprise a nucleotide sequence deletion in a sequence encoding a CH1 domain (or CH1 domain and hinge region) of an immunoglobulin gamma (IgG) gene but that are capable of expressing an IgM that does not lack a functional CH1 domain, and in particular mice that are capable of making wild-type IgM molecules (*i.e.*, with CH1 domains) but that make heavy chain IgG antibodies devoid of a functional CH1 domain (or CH1 domain and hinge region).

BACKGROUND

[0002] In most animals, normal immunoglobulin heavy chains are only well-expressed when coupled with their cognate light chains. In humans, lone heavy chains are found in heavy chain disease that is manifested by dysfunctional heavy chains that lack sequences of the variable heavy, the CH1, or the variable heavy and CH1 domains. Heavy chains devoid of light chains are encountered in certain species of fish and in camels. Such heavy chains lack a functional CH1 domain and have non-human features in their heavy chain variable domains. Attempts have been made to make camelized antibodies by modifying mice to express camelized genes that mimic VHH domains found in camels or certain species of fish, in part by removal of IgM and IgG CH1 domains and conforming the heavy chain variable regions to resemble those of camels and/or certain species of fish. However, camelized antibodies would be expected to induce immune responses in non-camel animals.

[0003] There is a need in the art for genetically modified non-human animals that make heavy chain antibodies that have non-camelid VH domains.

BRIEF DESCRIPTION OF THE FIGURES**[0004]**

Figure 1 illustrates a wild-type IgG1 locus in a mouse (IgG1, top), showing the JH region gene segment fusing to a CH1 gene segment, followed by a hinge region, a CH2 gene segment, and a CH3 gene segment; an IgG1 locus targeted with a construct that deletes a CH1 domain (IgG1 Δ CH1, middle); and an IgG1 locus targeted with a construct that deletes both a CH1 domain and a hinge region (IgG1 Δ CH1- Δ hinge, bottom).

Figure 2 illustrates targeting a mouse IgG1 gene to make a genetically modified locus that expresses an IgG1 lacking a CH1 domain.

Figure 3 illustrates targeting a mouse IgG1 gene to make a genetically modified locus that expresses an IgG1 lacking a CH1 domain and lacking a hinge region.

Figure 4 illustrates targeting a mouse heavy chain constant region locus to make a genetically modified locus that expresses an IgG1 lacking a CH1 domain, and does not express an IgG2b or an IgG2a.

Figure 5 illustrates a mouse heavy chain constant region targeted with a construct that deletes a CH1 domain and deletes a hinge region and that deletes an IgG2b gene and an IgG2a gene.

Figure 6 illustrates a heavy chain constant region of a genetically modified mouse having an IgG1 that lacks a CH1 domain or lacks a CH1 domain and a hinge region (top), and a heavy chain constant region of a genetically modified mouse having an IgG1 that lacks a CH1 domain or lacks a CH1 domain and a hinge region, and that lacks an IgG2a gene and lacks an IgG2b gene (bottom).

Figure 7 shows Western blots of CHO cell supernatants from CHO cells engineered to independently express control (cytokine ectodomain fusion with a mouse Fc), chimeric (human VR)/(mouse Fc) heavy chain antibody lacking a CH1 domain (hVR-mFc Δ CH1), camelized chimeric (human VR)/(mouse Fc) heavy chain antibody lacking a CH1 domain (hVR*-mFc Δ CH1), chimeric (human VR)/(mouse Fc) heavy chain antibody (hVR-mFc), camelized chimeric (human VR)/(mouse Fc) heavy chain antibody (hVR*-mFc), mFc with (mFc) or without (mFc Δ CH1) a CH1 domain.

Figure 8 shows Western blot images from a reducing SDS-PAGE of mouse sera from a wild-type mouse (left) and from a genetically modified mouse whose IgG1 lacks a CH1 domain and lacks a hinge region (heterozygous) (right), blotted with anti-mouse IgG; schematics of the heavy chains are provided, as are molecular weight marker positions.

Figure 9 shows Western blot images from a non-reducing SDS-PAGE of mouse sera from a wild-type mouse (WT) and four genetically modified mice whose IgG1 lacks a CH1 domain and lacks a hinge region (homozygous; noted as HO 1, HO 2, HO 3, HO 4, respectively), blotted with anti-mouse IgG; each mouse (WT or HO) is represented by two lanes indicated by brackets above the lanes corresponding to 1:5 and 1:10 dilutions of serum for each animal (consecutive lanes from left to right for each).

Figure 10 provides a schematic diagram of a normal IgG1 antibody (left) and a heavy chain antibody that lacks a

CH1 domain and lacks a hinge region.

Figure 11 shows separate IgG1 and IgG2b serum immunoglobulin assays from wild type mice (WT) and genetically modified mice that contain an IgG1 lacking a CH1 domain and lacking a hinge region (HO; homozygous mouse that expresses a heavy chain antibody that lacks a CH1 domain and lacks a hinge region). Control is pooled human serum.

Figure 12 shows the protein sequences of eleven independent RT-PCR clones amplified from splenocyte RNA of mice bearing mouse heavy chain gene sequences at a modified endogenous mouse heavy chain locus devoid of IgG1 CH1 and hinge region sequences. B1 = SEQ ID NO:19; B2 = SEQ ID NO:21; B3 = SEQ ID NO:23; B5 = SEQ ID NO:25; D2 = SEQ ID NO:27; D5 = SEQ ID NO:29; D6 = SEQ ID NO:31; E2 = SEQ ID NO:33; E8 = SEQ ID NO:35; E10 = SEQ ID NO:37; F6 = SEQ ID NO:39. Lower case bases indicate non-germline bases resulting from either mutation and/or N addition during recombination. Dots represent artificial gaps in the sequence for proper alignment of framework (FR) and complementary determining regions (CDR), which are noted above the sequences. The first nine amino acids from the CH2 region of the endogenous IgG1 (CH2) constant region are shown for each clone.

Figure 13 shows the protein sequences of seven independent RT-PCR clones amplified from splenocyte RNA of mice bearing human heavy chain gene sequences at a modified endogenous mouse heavy chain locus devoid of an IgG1 CH1 region sequence. A8 = SEQ ID NO:51; C2 = SEQ ID NO:53; D9 = SEQ ID NO:55; C4 = SEQ ID NO:57; H8 = SEQ ID NO:59; A5 = SEQ ID NO:61; A2 = SEQ ID NO:63. Lower case bases indicate non-germline bases resulting from either mutation and/or N addition during recombination. Dots represent artificial gaps in the sequence for proper alignment of framework (FR) and complementary determining regions (CDR), which are noted above the sequences. The first seven amino acids of the 13 amino acid hinge region of the endogenous IgG1 (HINGE) constant region are shown for each clone.

SUMMARY

[0005] Genetically modified cells, non-human embryos, non-human animals and methods and compositions for making and using them are disclosed, wherein the animals are genetically modified to lack a functional CH1 sequence in an immunoglobulin G (IgG), optionally modified to lack a functional IgG hinge region on the modified IgG, and wherein the cells, embryos, and animals comprise a functional IgM CH1 sequence.

[0006] Hence a transgenic mouse is provided comprising a germline modification, which modification comprises: (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a); wherein the mouse comprises an intact IgM constant region gene, wherein the mouse expresses an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the mouse secretes said IgG heavy chain antibody into its serum.

[0007] In some aspects, the mice comprise a replacement of one or more, or all, endogenous mouse immunoglobulin heavy chain variable region gene segments with one or more human immunoglobulin heavy chain variable region gene segments. In some aspects, all endogenous mouse V, D, and J gene segments are replaced with one or more human V, one or more human D, and one or more human J gene segments.

[0008] The genetically modified mouse provided is one where the genetic modification comprises a modification of a nucleotide sequence encoding an IgG constant region, wherein the modification results in a loss of function of the CH1 domain of the IgG constant region. In one embodiment, the loss of function modification is a deletion of a nucleotide sequence encoding the CH1 domain, or a deletion within the nucleotide sequence encoding the CH1 domain.

[0009] In one embodiment, the IgG is selected from IgG1, IgG2a, IgG2b, and a combination thereof. In one embodiment, the IgG is an IgG1. In one embodiment, the IgG is an IgG1, an IgG2a, and an IgG2b.

[0010] In one embodiment, the modification further comprises a deletion of a nucleotide sequence for a hinge region of the IgG that comprises the CH1 modification.

[0011] In one embodiment, the genetically modified mouse is selected from a 129 strain, a C57BL/6 strain, and a mix of 129 x C57BL/6. In a specific embodiment, the mouse is 50% 129 and 50% C57BL/6.

[0012] In one embodiment, the genetically modified mouse is a 129 strain selected from the group consisting of a 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1/SV, 129S1/SvIm), 129S2, 129S4, 129S5, 129S9/SvEvH, 129S6 (129/SvEvTac), 129S7, 129S8, 129T1, 129T2 (see, e.g., Festing *et al.* (1999) Revised nomenclature for strain 129 mice, Mammalian Genome 10:836). In one embodiment the genetically modified mouse is a C57BL strain, in a specific embodiment selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, C57BL/Ola. In a specific embodiment, the genetically modified mouse is a mix of an aforementioned 129 strain and an aforementioned C57BL/6 strain. In another specific embodiment, the mouse is a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 strains. In a specific embodiment, the 129 strain of the mix is a 129S6 (129/SvEvTac) strain.

[0013] Also referred to is a mouse that comprises one or more unrearranged endogenous mouse heavy chain immunoglobulin variable region (mVR) gene segments operably linked to a modified IgG constant region sequence. In one instance the one or more mVR gene segments are from a mouse VH gene family selected from VH1, VH3, VH5, VH7, VH14, and a combination thereof. In one instance, the one or more mVR gene segments are selected from a mVH 1-26, 1-42, 1-50, 1-58, 1-72, 3-6, 5-6, 7-1, 14-2, and a combination thereof.

[0014] In one embodiment, the mouse comprises a rearranged gene that encodes an FR1, FR2, and an FR3 in an IgG heavy chain that lacks a functional CH1 region, wherein the FR1, FR2, and FR3 are each independently at least 90%, 95%, 96%, 97%, 98%, or 99% identical to an FR1, FR2, and FR3 derived from a mVH germline sequence selected from a VH1, VH3, VH5, VH7, and VH14 gene family. In one embodiment, the mVH germline sequence is selected from a 1-26, 1-42, 1-50, 1-58, 1-72, 3-6, 5-6, 7-1, and 14-2 sequence.

[0015] In one embodiment, the mouse comprises a CDR3 derived from a DH gene segment selected from DH 1-1, 2-14, 3-1, 3-2, 3-3, 4-1, and a combination thereof. In one embodiment, the mouse CDR3 comprises a sequence encoded by a JH that is a JH1, JH2, JH3, or JH4.

[0016] In one embodiment, the mouse comprises a rearranged antibody sequence that encodes a CDR3 that is derived from a rearrangement of a DH 1-1, 2-14, 3-1, 3-2, 3-3, 4-1, and a JH1, JH2, JH3, or JH4.

[0017] In one embodiment, the mouse comprises a rearranged gene that encodes an FR4 in an IgG heavy chain that lacks a functional CH1 region, wherein the FR4 is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to an FR4 encoded by a rearrangement of a DH1-1, 2-14, 3-1, 3-2, 3-3, or 4-1 with a JH1, JH2, JH3, or JH4.

[0018] In one embodiment, the mouse comprises an unrearranged human heavy chain immunoglobulin variable region (hVR) gene segment at an endogenous mouse heavy chain variable region locus. The unrearranged hVR gene segment is operably linked to the modified IgG constant region sequence at an endogenous mouse heavy chain variable region locus. In one embodiment, the hVR gene segments are from a human VH gene family selected from VH1, VH3, VH4, and a combination thereof. In one embodiment, the one or more hVR gene segments are selected from 1-2, 1-8, 1-18, 1-46, 1-69, 3-21, 3-72, and 4-59. In a specific embodiment, the one or more hVR gene segments are selected from 1-8, 1-18, and 1-69.

[0019] In one embodiment, all or substantially all mouse heavy chain V gene segments are replaced by the one or more human heavy chain V gene segments. In one embodiment, all mouse heavy chain V and D gene segments are replaced by the one or more human heavy chain V and D gene segments. In one embodiment, all mouse heavy chain V, D, and J gene segments are replaced with the one or more human heavy chain V, one or more human heavy chain D, and one or more human heavy chain J gene segments. In these embodiments, the human heavy chain V and/or D and/or J gene segments are at the mouse endogenous heavy chain locus and are operably linked to the modified mouse constant region gene(s).

[0020] In one embodiment, the mouse comprises a nucleotide sequence that encodes a FR1, FR2, and FR3 sequence of an IgG heavy chain that lacks a functional CH1 region, that is at least 80% identical to an FR1, FR2, and FR3 from a human germline nucleotide sequence of a 1-8, 1-18, or 1-69 human immunoglobulin heavy chain variable region gene segment; wherein the FR1 + FR2 + FR3 sequence of the modified mouse is optimally aligned with the recited human germline sequence without regard to the sequence of the CDRs of the mouse and human sequences (*i.e.*, optimally aligning the FRs while not considering the identities of amino acids of any CDRs in the comparison). In specific embodiments, the FR1, FR2, and FR3 are about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a human germline nucleotide sequence of a FR1 + FR2 + FR3 of a heavy chain variable region gene segment that is a 1-8, 1-18, or 1-69 gene segment.

[0021] In one embodiment, the mouse further comprises a FR4 that is at least 80% identical to a FR4 formed by a human D6-19/J6 rearrangement, a D6-7/J4 rearrangement, a D4-4/J4 rearrangement, a D6-6/J2 rearrangement, a D3-16/J6 rearrangement, a D6-6/J4 rearrangement, and a D1-7/J4 rearrangement. In specific embodiments, the FR4 is about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an FR4 formed by the aforementioned D/J rearrangement.

[0022] In one embodiment, the mouse comprises a nucleotide sequence encoding a FR1 whose amino acid sequence differs by no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 amino acids from a FR1 encoded by a germline sequence of human heavy chain variable region gene segment selected from V1-8, V1-18, and V1-69. In a specific embodiment, the nucleotide sequence encoding the FR1 is a rearranged sequence operably linked to a sequence encoding an IgG constant region that lacks a functional CH1 sequence.

[0023] In one embodiment, the mouse comprises a nucleotide sequence encoding a FR2 whose amino acid sequence differs by no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 amino acids from a FR2 encoded by a germline sequence of human heavy chain variable region gene segment selected from V1-8, V1-18, and V1-69. In a specific embodiment, the nucleotide sequence encoding the FR2 is a rearranged sequence operably linked to a sequence encoding an IgG constant region that lacks a functional CH1 sequence.

[0024] In one embodiment, the mouse comprises a nucleotide sequence encoding a FR3 whose amino acid sequence differs by no more than 1, no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, or no more than 11 amino acids from a FR3 encoded by a

germline sequence of human heavy chain variable region gene segment selected from V1-8, V1-18, and V1-69. In a specific embodiment, the nucleotide sequence encoding the FR3 is a rearranged sequence operably linked to a sequence encoding an IgG constant region that lacks a functional CH1 sequence.

[0025] In one embodiment, the mouse comprises a nucleotide sequence encoding a FR4 whose amino acid sequence differs by no more than 1, no more than 2, or no more than 3 amino acids from a FR4 amino acid sequence encoded by a rearrangement of a human D6-19/J6, a D6-7/J4, a D4-4/J4, a D6-6/J2, a D3-16/J6, a D6-6/J4, and a D1-7/J4. In a specific embodiment, the nucleotide sequence encoding the FR4 is a rearranged sequence operably linked to a sequence encoding an IgG constant region that lacks a functional CH1 sequence.

[0026] In one embodiment, the mouse comprises a nucleotide sequence encoding a heavy chain CDR3 derived from a human heavy chain D region gene segment (hDH). In one embodiment, the hDH is selected from D1-7, D3-16, D4-4, D6-6, D6-7, and D6-19.

[0027] In one embodiment, the mouse comprises a nucleotide sequence encoding a heavy chain CDR3 derived from a human heavy chain joining gene segment (JH). In a specific embodiment, the JH is selected from J2, J4, and J6.

[0028] In one embodiment, the mouse comprises a heavy chain CDR3 encoded by a nucleotide sequence derived from a human DH and a human JH rearrangement. In a specific embodiment, the CDR3 is derived from a D1-7/J4, D3-16/J6, D4-4/J4, D6-6/J2, D6-6/J4, D6-7/J4, or a D6-19/J6 rearrangement.

[0029] In one embodiment, the mouse comprises a replacement of an endogenous mVR gene segment with an hVR gene segment. The replacement of the mVR gene segment with the hVR gene segment is on the same allele as the modified heavy chain constant region.

[0030] In one embodiment, 90-100% of mVR gene segments are replaced with at least one hVR gene segment. In a specific embodiment, all or substantially all of the endogenous mVR gene segments are replaced with at least one hVR gene segment. In one embodiment, the replacement is with at least 18, at least 39, or at least 80 or 81 hVR gene segments. In one embodiment, the replacement is with at least 12 functional hVR gene segments, at least 25 functional hVR gene segments, or at least 43 functional hVR gene segments.

[0031] Also referred to is a genetically modified mouse that comprises a transgene that comprises at least one unrearranged hVR gene segment, at least one unrearranged human D segment, at least one unrearranged human J segment, and at least one human heavy chain constant sequence. In one instance, the endogenous mouse heavy chain variable region and kappa light chain variable region loci are functionally silenced. In a specific instance, the mouse is capable of *trans*-switching to produce a chimeric human/mouse antibody comprising a human heavy chain variable domain contiguous with a mouse IgG sequence that lacks a functional CH1 domain and, optionally, lacks a hinge region of the IgG that lacks the functional CH1 domain. In a specific instance, the transgene further comprises an IgG sequence that lacks a CH1 domain, and optionally comprises an IgM having a functional CH1 domain. In a further specific instance, the IgG sequence lacks a hinge region.

[0032] In one embodiment, the mouse comprises a first heavy chain variable region allele and a second heavy chain variable region allele, wherein the first allele and the second allele are both from the same mouse strain. In one embodiment, the first allele is from a first mouse strain and the second allele is from a second mouse strain. In one embodiment, one allele of the first and the second alleles comprises a replacement of an mVR with at least one hVR. In another embodiment, both alleles comprise a replacement of an mVR with at least one hVR.

[0033] In one aspect, the genetically modified mouse provided, is one where the mouse expresses an IgM that comprises a CH1 domain, and the mouse expresses an IgG that lacks a functional CH1 domain or that expresses an IgG that lacks both a functional CH1 domain and that lacks a functional hinge region.

[0034] In one embodiment, the IgG is an IgG1.

[0035] In one embodiment, the mouse expresses four IgGs that are: a modified IgG1 and a wild-type IgG3, IgG2a, and IgG2b. In another embodiment, the mouse expresses no more than two IgGs that are: a modified IgG1 and a wild-type IgG3. In a specific embodiment the mouse expresses heavy chain isotypes that are: a wild-type IgM, a wild-type IgD, a wild-type IgG3, a modified IgG1, a wild-type IgG2a, a wild-type IgG2b, a wild-type IgA, and a wild-type IgE. In another specific embodiment, the mouse expresses heavy chain isotypes that are: a wild-type IgM, a wild-type IgD, a wild-type IgG3, a modified IgG1, a wild-type IgA, and a wild-type IgE. In various embodiments, the modification of the IgG1 comprises a deletion of a CH1 domain and, optionally, a deletion of a hinge region.

[0036] In one embodiment, the mouse is from a strain selected from 129, C56BL/6, a mixed 129 x C57BL/6.

[0037] In one aspect, the mouse expresses a heavy chain antibody, wherein the heavy chain antibody consists essentially of a dimeric heavy chain, wherein the heavy chain lacks a functional CH1 domain or lacks both a functional CH1 domain and a functional hinge region, the heavy chain comprises a human heavy chain variable domain that comprises a sequence that is not identical to a human heavy chain variable domain encoded by a germline variable region gene, and the heavy chain comprises a human or mouse CH2 domain and a human or mouse CH3 domain, wherein the mouse expresses a wild-type human or mouse IgM.

[0038] In one embodiment, the mouse comprises a functional immunoglobulin light chain gene locus.

[Deleted]

[0039] In one embodiment, the heavy chain antibody consists essentially of a dimeric heavy chain lacking a functional CH1 domain and lacking a functional hinge region, wherein the heavy chain comprises a human variable domain that comprises at least one somatic mutation and comprises a CH2 domain and a CH3 domain. In a specific embodiment, the CH2 domain and the CH3 domain are independently selected from mouse and human domains. In a specific embodiment, both the CH2 and the CH3 domain are human; in another embodiment, both the CH2 and the CH3 domain are mouse.

[0040] Also referred to is a heavy chain antibody, wherein the heavy chain antibody comprises a heavy chain comprising a non-camelid variable domain and a heavy chain constant region lacking a CH1 domain.

[0041] In one instance, the heavy chain antibody further lacks a hinge region.

[0042] In one instance, the heavy chain antibody comprises a constant region that consists essentially of a hinge region, a CH2 domain, and a CH3 domain. In another embodiment, the heavy chain antibody comprises a constant region that consists essentially of a CH2 domain and a CH3 domain.

[0043] In one instance, the non-camelid variable domain is a somatically mutated human or mouse heavy chain variable domain obtained from an IgM- or an IgG-encoding nucleotide sequence of a B cell from a mouse or a genetically modified mouse comprising a human heavy chain variable region gene segment. In a specific instance, the mouse comprises a humanized heavy chain variable region gene segment. In another instance, the mouse comprises a replacement of the endogenous mouse heavy chain variable region gene segment locus with at least one human variable region gene segment. In another instance, the mouse comprises a replacement of the endogenous mouse heavy chain locus with at least one human variable gene segment, at least one human D gene segment, and at least one human J gene segment. In a specific instance, the endogenous mouse immunoglobulin variable region locus is all or substantially all replaced with a human immunoglobulin variable region locus comprising a plurality of human V, D, and J gene segments.

[0044] The non-camelid variable domain is a human variable domain. In another instance, the non-camelid variable domain is a human variable domain comprising one or more camelizing modifications. In a specific instance, the camelizing modification is selected from L11S, V37F, G44E, L45C, L45R, and W47G (Kabat numbering). In a specific instance, the camelizing modification is selected from V37F, G44E, and L45C. In a specific instance, the heavy chain variable domain comprises a complementarity determining region 3 (CDR3) that comprises two cysteines.

[0045] In one instance, the heavy chain antibody comprises a dimer of a first heavy chain comprising a first heavy chain variable domain and a second heavy chain comprising a second heavy chain variable domain, wherein each of the first and the second heavy chains lacks a CH1 domain (or lacks a CH1 domain and a hinge region). In one instance, the human variable domain of the first heavy chain of the dimer binds a first epitope, and the human variable domain of the second heavy chain of the dimer binds a second epitope, wherein the first and the second epitope are not identical. In a specific instance, the heavy chain variable domains of the first and the second heavy chains comprise human heavy chain variable domains and/or human heavy chain FR regions as described herein.

[0046] Also provided is an isolated cell wherein the cell comprises a modification comprising: (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a); wherein the cell comprises an intact IgM constant region gene, wherein the cell expresses an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the cell secretes said IgG heavy chain antibody. Also referred to is a genetically modified non-human cell, wherein the genetic modification comprises a deletion of an IgG CH1 domain and the cell expresses a functional IgM. In a specific instance, the cell comprises an IgM gene comprising a sequence encoding a CH1 domain. Further provided is an embryonic stem (ES) cell that comprises a modification comprising: (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a); wherein the ES cell comprises an intact IgM constant region gene, wherein the ES cell can give rise to a mouse expressing an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the mouse secretes said IgG heavy chain antibody into its serum.

[0047] In one embodiment, the cell is selected from a mouse ES cell, a pluripotent cell, and a totipotent cell.

[0048] Also referred to is a genetically modified mouse embryo, wherein the genetic modification comprises a modification as described herein. In one embodiment, the genetic modification comprises a deletion of an IgG CH1 domain and the mouse embryo expresses a functional IgM. In a specific embodiment, the mouse embryo comprises an IgM gene comprising a CH1 domain.

[Deleted]

[0049] Also referred to is a mouse embryo comprising a donor cell, wherein the donor cell is genetically modified, and wherein the genetic modification is a modification as described herein. In one instance, the genetic modification comprises a deletion of an IgG CH1 domain and the cell comprises an IgM gene comprising a CH1 domain.

[0050] In one instance, the donor cell is a mouse ES cell.

[0051] Also referred to is a DNA construct, wherein the DNA construct comprises (a) a mouse homology arm homologous to a first sequence 5' and immediately adjacent to the start of an IgG CH1 region; (b) a marker or drug selection cassette; and, (c) a homology arm homologous to a second sequence 3' and immediately adjacent to the end of an IgG CH1 region or, alternatively, a homology arm homologous to a second sequence 3' and immediately adjacent to the end of an IgG hinge region.

[0052] Also referred to is a method for making an antibody that lacks a CH1 domain, comprising: (a) immunizing a mouse as described herein that lacks a functional CH1 domain in an IgG or lacks a functional CH1 domain and lacks a functional hinge region in the IgG, wherein the mouse expresses an IgM that comprises a functional CH1 domain; (b) maintaining the mouse under conditions sufficient for the mouse to make an antibody; (c) identifying an antibody made by the mouse that lacks a functional CH1 domain or that lacks a functional hinge region; and, (d) isolating from the mouse the antibody, a cell that makes the antibody, or a nucleotide sequence that encodes a sequence of the antibody.

[0053] In one embodiment, the mouse comprises a functional immunoglobulin light chain gene locus.

[0054] Also referred to is a method for humanizing a mouse heavy chain antibody, comprising immunizing a genetically modified mouse that makes heavy chain antibodies with an antigen of interest, allowing the mouse to mount an immune response, identifying a mouse VH region of the mouse that is encoded in a B cell of the mouse, wherein the B cell specifically binds the antigen of interest, and humanizing the VH region.

[0055] In one instance, the genetically modified mouse that makes heavy chain antibodies is a mouse as described herein. In one instance, the mouse comprises at least one mVR gene segment operably linked to a heavy chain constant locus that comprises an intact IgM gene and that comprises an IgG gene that lacks a CH1 domain or that lacks a CH1 domain and lacks a hinge domain. In one instance, the IgG gene is an IgG1 gene. In one instance, the IgG gene is selected from IgG1, IgG2A, IgG2B, IgG3, and a combination thereof.

[0056] In one instance, the method further comprises cloning a nucleotide sequence encoding the humanized VH region onto a nucleotide sequence of a human immunoglobulin constant region.

[0057] In one instance, the mouse mVR gene segment is from a mouse VH gene family selected from VH1 and VH14, and the humanization comprises replacing a mouse framework of VH1 or VH14 with a framework from a human VH1 gene. In one embodiment, the human VH1 gene is selected from 1-2, 1-3, 1-8, 1-17, 1-18, 1-24, 1-45, 1-46, 1-58, and 1-69. In specific instances, the mVR gene is a 1-58 gene and the human gene is a 1-18 gene; the mVR gene is a 1-26 gene and the human gene is a 1-2 gene; the mVR gene is a 1-50 gene and the human gene is a 1-46 gene; the mVR gene is a 1-17 gene and the human gene is a 1-2 gene; the mVR gene is a 1-42 gene and the human gene is a 1-2 gene; the mVR is a 14-1 gene and the human gene is a 1-2 gene; or the mVR is a 14-2 gene and the human gene is a 1-2 gene.

[0058] In one instance, the mVR gene segment is from a mouse VH gene selected from a VH4, VH5, VH6, VH7, VH10, VH11, and VH13 gene, and the humanization comprises replacing a mouse framework with a framework from a human VH3 gene. In one instance, the human VH3 gene is selected from 3-7, 3-9, 3-11, 3-13, 3-15, 3-16, 3-20, 3-21, 3-23, 3-30, 3-33, 3-35, 3-38, 3-43, 3-48, 3-49, 3-53, 3-64, 3-66, 3-72, 3-73, and 3-74. In a specific instance, the mVR gene is a 7-1 gene and the human gene is a 3-72 gene; the mVR gene is a 3-6 gene and the human gene is a 4-59 gene; the mVR gene is a 5-6 gene and the human gene is a 3-21 gene.

[0059] In one instance, the mVR gene segment is from a mouse VH gene family selected from VH3 and VH12, and the humanization comprises replacing a mouse framework with a framework from a human VH4 gene. In one instance, the human VH4 gene is selected from 4-4, 4-28, 4-31, 4-34, 4-39, 4-59, and 4-61.

[0060] In one instance, the mVR gene segment is from a mouse VH4 gene family, and the humanization comprises replacing a mouse VH4 framework with a framework from a human VH6 gene. In one instance, the human VH6 gene is 6-1.

[0061] In one instance, the mVR gene segment is from a mouse VH9 gene family, and the humanization comprises replacing a mouse VH9 framework with a framework from a human VH gene of the human VH7 family. In one instance, the human VH gene is selected from 7-4-1 and 7-81.

[0062] In one instance, the humanization further comprises making one or more conservative or non-conservative substitutions, one or more deletions, and/or one or more insertions in a mouse CDR such that the mouse CDR corresponds more closely to a human CDR.

[0063] In one instance, the humanization further comprises making one or more conservative or nonconservative substitutions, one or more deletions, and/or one or more insertions in a human framework such that the human framework corresponds more closely to the mouse framework.

[0064] In one aspect, the genetically modified mouse provided is one that comprises a functional immunoglobulin light

chain gene, wherein the mouse expresses a heavy chain antibody that lacks a light chain and that lacks a CH1 region or that lacks a CH1 region and a hinge region.

[0065] The mouse comprises an immunoglobulin gene that lacks a sequence encoding a CH1 region, or lacks a sequence encoding a hinge and a CH1 region. The immunoglobulin gene that lacks the sequence is one or more heavy chain constant genes. In a specific embodiment, the immunoglobulin gene that lacks the sequence is selected from an IgG1, IgG2a, IgG2b, and IgG3 gene. The mouse comprises an intact IgM constant region gene.

[0066] In one embodiment, the antibody is expressed in response to an antigen, and the antibody specifically binds the antigen.

[0067] In one embodiment, the antibody comprises a mouse VH domain. In a specific embodiment, the mouse VH domain comprises a mouse VH gene segment selected from 1-26, 1-42, 1-50, 1-58, 1-72, 3-6, 5-6, 7-1, 14-1, and 14-2.

[0068] In one embodiment, the antibody comprises a human VH domain. In a specific embodiment, the human VH domain comprises a sequence derived from a human VH gene segment selected from 1-2, 1-18, 1-46, 3-21, 3-72, and 4-59.

[0069] In one aspect, the genetically modified mouse provided expresses a binding protein that consists essentially of two IgG1 heavy chains that each lack a CH1 domain, wherein the mouse expresses an IgM that comprises a CH1 region, and wherein the mouse is incapable of expressing from its genome an mRNA that comprises a nucleotide sequence encoding a CH1 domain of an IgG1.

[0070] In one embodiment, the immunoglobulin heavy chains that each lack a CH1 domain consist essentially of, from N-terminal to C-terminal, a human heavy chain immunoglobulin variable region, optionally a hinge region, a mouse CH2 region, and a mouse CH3 region. In a specific embodiment, the heavy chain immunoglobulin variable region is a human variable region, a hinge region is present, and the mouse comprises a functional immunoglobulin light chain gene locus.

[0071] In one aspect, the mouse provided expresses a heavy chain antibody that lacks a light chain and that lacks a CH1 region in whole or in part, wherein the mouse expresses a B cell receptor on a B cell, wherein the B cell receptor on its surface displays a binding molecule that comprises an immunoglobulin heavy chain variable domain fused directly to an immunoglobulin hinge region or fused directly to a CH2 region, wherein the binding molecule lacks a CH1 region. In one embodiment, the binding molecule comprises an IgG1 CH2 and CH3 region.

[0072] Also referred to is a method for making a heavy chain antibody, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises an IgG gene that lacks a sequence encoding a CH1 region, wherein the mouse comprises an intact IgM constant region gene, allowing the mouse to mount an immune response against the antigen of interest, and isolating from the mouse a cell or protein that specifically recognizes the antigen of interest, wherein the cell or protein comprises a heavy chain antibody that lacks a CH1 domain and that lacks a cognate light chain and that specifically binds the antigen of interest.

[0073] In one embodiment, the mouse comprises a functional light chain gene. In one embodiment, the mouse comprises a functional light chain gene selected from lambda, kappa, and a combination thereof.

[0074] In one embodiment, the mouse comprises a replacement of all or substantially all mouse heavy chain V, D, J gene segments with one or more human V, D, J gene segments.

[0075] In one embodiment, the IgG gene that lacks the sequence encoding a CH1 is selected from an IgG1, IgG2a, IgG2b, IgG3, and a combination thereof.

[0076] In one embodiment, the IgG gene that lacks the CH1 sequence is IgG1, and the mouse lacks a gene encoding IgG2a, IgG2b, IgG3, or a combination thereof. In one embodiment, the IgG gene that lacks the CH1 sequence is IgG2a, and the mouse lacks a gene encoding IgG1, IgG2b, IgG3, or a combination thereof. In one embodiment, the IgG gene that lacks the CH1 sequence is IgG2b, and the mouse lacks a gene encoding IgG1, IgG2a, IgG3, or a combination thereof. In one embodiment, the IgG gene that lacks the CH1 sequence is IgG3, and the mouse lacks a gene encoding IgG1, IgG2a, IgG2b, or a combination thereof.

[0077] In one embodiment, the mouse comprises a B cell that bears on its surface a B cell receptor, wherein the B cell receptor comprises a rearranged heavy chain VDJ that binds the antigen of interest, and wherein the B cell receptor comprises an IgM that comprises a CH1 region, and wherein the IgM comprises a light chain. In one embodiment, the light chain is VJ rearranged. In a specific embodiment, the light chain is a kappa or a lambda light chain that is cognate with the rearranged heavy chain VDJ that binds the antigen of interest.

[0078] Also referred to is a mouse heavy chain antibody, human heavy chain antibody, or chimeric human/mouse heavy chain antibody made in a mouse according to the invention.

[0079] Also referred to is a mouse heavy chain antibody, human heavy chain antibody, chimeric human/mouse heavy chain antibody, or humanized heavy chain antibody made using a heavy chain variable region nucleotide sequence or fragment thereof made in a mouse according to the invention is provided.

[0080] Other embodiments are described and will become apparent to those skilled in the art from a review of the ensuing detailed description.

DETAILED DESCRIPTION

[0081] The invention is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the claims.

[0082] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, particular methods and materials are now described.

CH1 Domains and Antibody Production

[0083] Genetically modified mice are provided that make antibodies that lack a CH1 domain, including heavy chain antibodies, *i.e.*, antibodies that lack light chains. The genetically modified mice comprise a genetic modification that includes a lack of a functional immunoglobulin heavy chain domain (a CH1 domain), *e.g.*, an IgG1 CH1 domain, and in some embodiments a further modification comprising a deletion of a hinge region in the immunoglobulin heavy chain that lacks the functional CH1 domain, wherein the mice expresses a functional IgM. Other modifications include rendering isotypes other than IgG1 to be nonfunctional, *e.g.*, making deletions in genes, or deletions of genes, for IgD, IgG3, IgG2a, IgG2b, IgA, and IgE.

[0084] A transgenic mouse is provided comprising a germline modification, which modification comprises: (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a); wherein the mouse comprises an intact IgM constant region gene, wherein the mouse expresses an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the mouse secretes said IgG heavy chain antibody into its serum. Genetically modified non-human embryos, cells, and targeting constructs for making the mice, non-human embryos, and cells are also described.

[0085] Efforts at making genetically modified cells that can make heavy chain antibodies (*i.e.*, antibodies that lack a light chain) have focused on mimicking heavy chain antibodies in other species, *e.g.*, in camelids and certain fish. This approach has been used to genetically modify a mouse ES cell to delete CH1 domains in immunoglobulin constant region genes of IgMs and IgGs, and also to introduce heavy chain variable regions into the ES cell that are camelid, or camelized (*i.e.*, VHH or VHH-like). The deletion of IgM and IgG CH1 domains is undertaken presumably to prevent formation of endogenous, natural antibodies to compete with camelized antibody formation from a genetically modified locus. The addition of VHH gene segments is undertaken presumably to mimic heavy chain antibody formation in combination with the CH1 deletion. Heavy chain antibodies from such animals will contain the VHH gene segment. VHH gene segments are presumably thought to be necessary for the proper expression of a heavy chain antibody, since *in vitro* studies indicate that non-camelid VH domains do not satisfactorily form expressible heavy chain antibodies when present in heavy chains lacking a CH1 domain.

[0086] In camelids, however (and in some cartilaginous fish), genes are present that include CH1 domains, or CH1-like domains. VHH-containing antibodies that lack CH1 domains are believed to result from RNA splicing or from rearrangement of DNA sequences that can encode a CH1 region. Thus, even camelids have retained DNA sequences encoding CH1 regions. Because humans (under some circumstances) can make heavy chain antibodies lacking a CH1 region in whole or in part (*e.g.*, in human heavy chain disease), it might be possible to compel non-camelids, such as mice, to form heavy chains lacking a CH1 region under a given set of circumstances. This approach relies upon not disturbing the germline structure of a CH, but instead rendering the animal's light chain locus nonfunctional. This approach assumes that with a nonfunctional light chain locus those heavy chains that require a cognate light chain for expression (*e.g.*, full-length heavy chains having CH1 regions) are not made due to the lack of any kappa or lambda light chain, such that only those heavy chains that can express and secrete without a light chain (*i.e.*, heavy chains lacking a CH1 region) will be expressed and secreted. The approach relies upon the absence of functional kappa or lambda gene segments that can rearrange to form a functional light chain gene, and on the absence of any functional rearranged light chain gene, and thus requires a genetic manipulation (*e.g.*, a knockout) to destroy functionality of both germline light chain loci. The approach relies upon "natural" processes leading to non-use of the endogenous CH1 nucleotide sequence, and that the "natural" process of CH1 silencing occurs in class switching. There does not appear to be any possibility of using such a process in any animal that contains a functional light chain gene. Furthermore, it appears that the "natural" process includes the synthesis of large amounts of normal RNA, *i.e.*, RNA that includes a region encoding a CH1 region.

[0087] Compositions and methods are referred to for making the mouse that makes an antibody that lacks an immunoglobulin CH1 domain (and optionally a hinge region), including heavy chain antibodies, and including antibodies that comprise VH domains (*e.g.*, mouse or human VH domains). The methods include selectively rendering an endogenous

non-IgM CH1 region to be nonfunctional (e.g., by a deletion of a sequence of a CH1 domain), and employing unrearranged human variable region (hVR) gene segments at the endogenous mouse variable region locus to make a chimeric human/mouse antibody in a mouse. The deletion of the CH1 domain is made in one or more IgG genes, but not in an IgM gene. The approach selectively renders one or more IgG CH1 domains nonfunctional while retaining a functional IgM. In addition to a deletion of the one or more IgG CH1 domains, a further embodiment provides for deleting or rendering nonfunctional the hinge region of the IgG(s) in which the CH1 domain is deleted or rendered nonfunctional.

[0088] The IgG CH1 deletion approach employs a relatively conservative disruption in natural B cell development in the animal, because not all Ig isotypes of the genetically modified non-human animal will exhibit a nonfunctional CH1 or a deletion of the CH1 domain (and, optionally, hinge). Thus, the CH1 modification does not occur in IgM molecules and thus does not affect those steps in early B cell development that depend on an IgM having a functional CH1. Because the IgM is not modified, animals bearing one or more deletions of the CH1 domain of an IgG (and optionally a hinge region of the IgG), but not an the CH1 domain of an IgM, should be able to process a satisfactorily large repertoire of variable regions in clonal selection steps prior to presentation of the variable domain in the context of an IgG. Thus in various embodiments, any deleterious affect of the genetic modification(s) on the diversity of variable regions available for use in a heavy chain antibody should not negatively impact the pool of variable regions available for selection in an IgG context. Further, where the CH1 sequence that is rendered nonfunctional (e.g., deleted) in the germline is an IgG1, the mouse will lack the ability to make any RNA that encodes a CH1 domain.

[0089] Genetically modifying a non-human animal to render a CH1 domain or a CH1 domain and a hinge region of one or more IgG isotypes nonfunctional may result in a mouse that is able to select, from a full or substantially full repertoire of VH regions, a suitable VH region to express in a heavy chain antibody. Selectively modifying IgG isotypes (but not IgM) avoids a potential reduction in the number of VH regions that survive selection due to a lack of a CH1 domain or a lack of a CH1 domain in IgM. Thus, a fuller repertoire of VH regions is available for selection in the context of an IgG (that lacks a CH1 domain or that lacks a CH1 domain and that lacks a hinge region). Thus, selection of a VH domain in a genetically modified mouse in accordance with the invention does not depend, e.g., on which VH domain might help overcome early IgM-dependent B cell developmental hurdles that are due to modified IgM structures. Instead, early IgM-dependent steps should occur as normal, resulting in a large repertoire of heavy chains available for selection as to their suitability to express in the context of an IgG that lacks a CH1 domain or that lacks a CH1 domain and lacks a hinge region.

[0090] Thus, in various embodiments, a genetically modified mouse in accordance with the invention should maintain functional IgM expression, which should provide an opportunity for a more natural clonal selection process. For example, with a functional IgM (e.g., an IgM that does not lack a CH1 domain), both surrogate light chain and the cognate light chain will be able to associate through the IgM's CH1 domain and participate in selection processes in early B cell development. In a genetically modified mouse in accordance with the invention, it is believed that class switching to an IgG isotype is the first selection step where any selection of heavy chain variable domains that can be expressed in the context of a constant domain lacking a functional CH1 domain or lacking a functional CH1 domain and a functional hinge is encountered.

IgM in B Cell Development

[0091] Although observations in camelids, certain fish, and in pathological conditions reveal that under some circumstances an antibody that lacks a CH1 domain of its heavy chain constant region can be expressed in the absence of a cognate light chain, normal development of antibody-producing B cells generally requires the presence of a CH1 domain. All heavy chain isotypes, including IgM, comprise a CH1 domain. Both the surrogate light chain and a cognate light chain are believed to interact with a given heavy chain through the heavy chain's CH1 domain in the context of an IgM. To the extent that development of heavy chain antibodies depends upon structural integrity or functionality of an IgM isotype heavy chain, disruption of the IgM's structural integrity or function would be undesirable.

[0092] Normal development of antibodies requires that antibodies survive throughout a multiplicity of complex selection schemes that result in the survival and ultimate expression of functional and useful antibodies. Disruptions in antibody structure can prove deleterious to the survival and ultimate expression of an antibody to the extent that the structural disruption results in the inability of the antibody to effectively compete and evolve to the satisfaction of one or more of nature's antibody selection schemes.

[0093] Early in antibody development, antibody heavy chains undergo a selection process wherein nature chooses, through a variety of selection schemes, suitable heavy chains to undergo further selection to eventually form functional and affinity-matured antibodies. Antibody heavy chains expressed from recombined heavy chain gene segments in progenitor B cells (or, pro-B cells) are normally paired with a surrogate light chain for presentation on the surface of the pro-B cell in an IgM isotype to form a structure (which includes other co-receptors) referred to as a pre-B cell receptor, or pre-BCR. Once the pre-BCR is presented on the cell surface, the pre-BCR is believed to signal its appropriate formation of the complex to the cell, effectively instructing the cell that the heavy chain has passed this early selection step. Thus

the cell is informed that the heavy chain may undergo further selection. If the heavy chain contains a defect that is deleterious to the formation of a pre-BCR when presented in the context of an IgM and a surrogate light chain, the cell will undergo apoptosis. If the cell undergoes apoptosis, the usefulness, or contribution to diversity, of the heavy chain variable region of the heavy chain will be lost. Thus, a very early step in antibody selection requires presentation of the heavy chain together with a surrogate light chain in the context of an IgM isotype. The surrogate light chain is believed to interact with IgM at least in part through IgM's CH1 domain. A failure or disruption in antibody structure at this early juncture (e.g., a nonfunctional CH1 domain) can result in clonal selection failure, loss of the pro-B cell that expresses the heavy chain, and loss of the possibility of employing the particular heavy chain variable domain in a useful antibody.

[0094] Once the cell bearing the pre-BCR passes this selection step, the next selection step requires that the heavy chain be paired with a cognate light chain (e.g., either kappa or lambda in mice and humans). The paired heavy chain/cognate light chain structure is again presented on the surface of the cell, now a naive pre-B cell, in the context of an IgM isotype through the IgM's CH1 domain. This complex on the surface results in a functional, membrane-bound, B cell receptor (BCR). This BCR is believed to signal to the cell that the heavy chain is suitable for further selection, and that the cell may now commit to expressing this particular light chain and proceed to further B cell maturation steps, including affinity maturation and class switching. If the heavy chain contains a defect that is deleterious to the formation of a BCR when presented in the context of an IgM and its cognate light chain, the cell will undergo apoptosis. If the cell undergoes apoptosis, the usefulness, or contribution to diversity, of the heavy chain variable region of the heavy chain will be lost. Thus, a very early step in antibody selection requires presentation of the heavy chain together with a surrogate light chain in the context of an IgM isotype. Again, a failure or disruption in antibody structure (e.g., a non-functional CH1 domain) at this early juncture can result in clonal selection failure and concomitant loss of the pre-B cell that expresses the heavy chain.

[0095] Having survived selection thus far, the pre-B cell that presents the heavy chain paired with its cognate light chain in the IgM context then undergoes a maturation process that ultimately results in class switching and further selection mechanisms in which the heavy chain and cognate light chain are presented on the B cell surface in the context of an IgG isotype. It would be at this step that any selection of IgG heavy chains that lack a CH1 domain or that lack a CH1 domain and a hinge region would occur. In mice according to the invention, it is believed that a normal repertoire of heavy chain variable regions would be available for selection based upon whether the variable domain would survive to be expressed in an IgG heavy chain that lacks a CH1 domain or that lacks a CH1 domain and a hinge region. In contrast, mice that have impaired IgMs would likely not present a full repertoire of heavy chain variable regions, since only those variable regions capable of surviving selection in the context of an impaired IgM would be available for class switching.

[0096] Thus, an animal lacking a functional IgM may experience a marked reduction in the ability to make a B cell population following rearrangement of otherwise suitable heavy chain variable gene segments. In such a case, even where an ample supply of heavy chain variable regions is available (i.e., the animal has a suitable number of heavy chain variable region gene segments capable of rearranging), a satisfactory population of B cells that display a desirable degree of diversity may not form because of an IgM impairment that mitigates against survival of a heavy chain during the selection process.

Heavy Chain Antibody Production with a Functional IgM Gene

[0097] A suitable number of rearranged heavy chain variable regions that can effectively survive selection when presented during B cell development in the context of an IgM is desirable to be maintained in order to generate sufficient diversity to make antibodies by immunizing a non-human animal with an immunogen of interest. Thus, a genetically modified mouse that comprises a nonfunctional CH1 domain or a nonfunctional CH1 domain and a nonfunctional hinge region in an immunoglobulin heavy chain should not comprise a CH1 deletion in both IgM alleles.

[0098] In some embodiments, it is not desirable to delete CH1 domains of all Ig isotypes in order to make a heavy chain antibody in a genetically modified mouse. Thus, methods and compositions are referred to for making a heavy chain antibody in a genetically modified mouse by disabling, deleting, or otherwise rendering non-functional a nucleotide sequence encoding a CH1 domain or fragment thereof of an IgG (and in some embodiments also disabling, deleting, or otherwise rendering nonfunctional a hinge region of the IgG) while allowing other isotypes (e.g., IgM) to retain functional CH1 domains. It is believed that functionality of other isotype CH1 domains (other than one or more selected IgG CH1 domains) results in a B cell development process that does not disrupt or substantially disrupt developmental steps in which the heavy chain variable domain is presented in the context of a non-IgG isotype, e.g., in an IgM isotype. Thus disruption of, e.g., IgM-dependent steps during B cell development is relatively minimized. Without limitation as to the invention (which is described by the claims) the inventors propose that minimalizing disruption of early selection steps associated with presentation of the heavy chain variable domain in an IgM context will result in more cells that bear the heavy chain variable regions surviving to undergo class-switching to an IgG isotype and selection in the context of an IgG that lacks a functional CH1 domain or that lacks a functional CH1 domain and lacks a functional hinge region.

[0099] Accordingly, a genetically modified mouse is provided, methods and compositions for making the mouse are also referred to, wherein the genetic modification results in lack of a functional CH1 domain (in a further embodiment lack of a functional hinge region) in an Ig domain that is not an IgM domain. In various embodiments, a sequence encoding CH1 or the CH1 and the hinge region (or a substantially functional portion thereof) are deleted in the genome of the genetically modified mouse. The genetically modified mouse is useful in making heavy chain antibodies (*i.e.*, antibodies that lack a light chain), including fully human antibodies (in a mouse genetically modified to include human immunoglobulin genes) and chimeric human/mouse antibodies (*e.g.*, in a mouse genetically modified to include human variable region gene segments, D regions, and J regions).

Heavy Chain Antibodies

[0100] Antibodies are useful as human therapeutics. Heavy chain antibodies, *i.e.*, antibodies that lack a light chain, are also useful as human therapeutics. Because heavy chain antibodies lack a light chain, they are smaller and thus expected to exhibit better tissue penetration than antibodies that contain light chains, yet have a similar or more favorable pharmacokinetic profile and yet retain similar effector function as compared to a conventional antibody. Because they are smaller, heavy chain antibodies are also capable of administration at a higher dose in a given volume. A frequent method of administering antibodies is by subcutaneous injection, and a reduction in administration volume for a given dosage of antibody can provide benefits to patients and avoid complications and pain due to subcutaneous injections of large volumes.

[0101] Another advantage of heavy chain antibodies is the ability to make bispecific antibodies by heterodimerizing heavy chains with specificity for two different epitopes in a single therapeutics. Because heavy chain antibodies lack a light chain, they are particularly suited for making bispecific antibodies since there is no requirement to engineer a common light chain that would not interfere with binding affinity or specificity of either heavy chain but also enable suitable expression of the bispecific antibody.

[0102] The genetically modified mice of the invention can be used to make a wide variety of heavy chain antibodies. The genetic modifications described herein can be made, *e.g.*, in any suitable mouse strain. The mouse strain can have any genetic background suitable for making a heavy chain antibody of choice. Some genetic backgrounds that encompass particular embodiments are provided below.

[0103] The genetically modified mouse can be a mouse comprising a genetic modification in accordance with the invention and one or more unrearranged human variable region gene segments, one or more unrearranged D region gene segments, and one or more unrearranged J region gene segments replacing an endogenous mouse heavy chain variable region locus. In such a mouse, the humanized variable region locus is capable of recombining to form a rearranged variable region gene upstream of endogenous mouse constant domain sequences (wherein one or more of the immunoglobulin constant region genes is modified as described herein). The mouse would thus be capable of making a chimeric human variable/mouse constant heavy chain antibody. Upon exposure to an immunogen of interest, the mouse would be capable of generating a heavy chain antibody in accordance with the invention that is affinity matured and capable of specifically binding an epitope of the immunogen of interest.

[0104] The genetically modified mouse can be a mouse comprising an endogenous mouse variable region that includes unrearranged endogenous mouse variable region gene segments, unrearranged endogenous mouse D region gene segments, and unrearranged endogenous mouse J region gene segments, wherein the mouse comprises a genetic modification of a mouse heavy chain constant region as described herein. The mouse would thus be capable of making a mouse heavy chain antibody. Upon exposure to an immunogen of interest, the mouse would be capable of generating a heavy chain antibody in accordance with the invention that is affinity matured and capable of specifically binding an epitope of the immunogen of interest.

[0105] Also referred to is a genetically modified mouse comprising a human transgene that comprises unrearranged human variable region gene segments, unrearranged human D gene segments, and unrearranged human J gene segments, a mu gene, and a sequence that allows for trans-switching. The mouse would further comprise a mouse heavy chain constant region modification as described herein. The mouse would be thus capable of making a fully human IgM antibody, and through *trans*-switching a chimeric human variable/mouse constant antibody, wherein the constant domain comprises a genetic modification as described herein. Upon exposure to an immunogen of interest, the mouse would be capable of generating a heavy chain antibody in accordance with the invention that is affinity matured and capable of specifically binding an epitope of the immunogen of interest.

In vitro Expression of Heavy Chain Antibodies

[0106] The inventors have established that a normal human or mouse heavy chain variable region (hVR or mVR) can be expressed in an *in vitro* system in the context of an IgG that lacks a functional CH1 domain. The inventors expressed an hVR from an unrearranged hVR minilocus in a mouse with a wild-type mouse IgM. The expressed hVR was cloned

onto an IgG2b lacking a CH1 domain, and the resulting hVR-IgG2b Δ CH1 expressed and was secreted by a CHO cell transiently transfected with the hVR-IgG2b Δ CH1 construct, effectively establishing that an hVR selected in a mouse having a wild-type IgM can be expressed and secreted by a cell when switched to an IgG lacking a functional CH1 domain, *i.e.*, as a heavy chain antibody.

[0107] The inventors constructed an *in vitro* system to express heavy chains that lack CH1 domains and that have hVRs or human camelized VRs (hVR*s) in CHO cells. The VRs were obtained from a RAG mouse that contained a replacement of the endogenous mouse heavy chain locus with a human heavy chain variable region minilocus (having three human V region gene segments, 6-1, 1-2, and 1-3, all human DH gene segments, and all human JH gene segments). The endogenous mouse immunoglobulin kappa and lambda light chain loci were intact and functional.

[0108] Chimeric heavy chain (hVR-mFc) and camelized heavy chain (hVR*-mFc) constructs were made, for expression in CHO cells, using the VR sequences obtained from the mouse bearing the minilocus described above. The chimeric heavy chains were the product of normal V-D-J recombination during B cell development in the mouse to form a functional antibody comprising a chimeric heavy chain (hVR-mFc) and a mouse light chain. hVR-mFc and hVR*-mFc constructs were made both having a CH1 domain and lacking a CH1 domain.

[0109] Transient transfection of hVR-mFc and hcVR-mFc constructs in CHO cells showed that in the absence of a CH1 domain, heavy chains having hVRs and hVR*s were expressed and remained soluble in the supernatant. In the presence of a CH1 domain, heavy chains containing either hVRs or hVR*s did not express in supernatant. This observation suggested that such heavy chain antibodies could be made without employing camelid VHH domains, *e.g.*, with human or mouse VH domains, in heavy chain antibodies that lacked a CH1 domain.

Humanized Heavy Chain Antibodies

[0110] To produce a humanized version of a heavy chain antibody, an animal homozygous for the modification is immunized with an antigen and once a specific immune response of the animal has been established, cells from the spleen of the immunized animal are fused with a suitable immortal cell (*e.g.*, a myeloma cell) to produce hybridoma cells. Alternatively, the antibodies can be obtained directly from B cells of the immunized animal. Supernatants from the hybridoma cells (or, *e.g.*, from isolated B cells) are screened for the presence of antibody by enzyme-linked immunosorbent assay (ELISA) and antibodies specific for the antigen can be selected based on desired characteristics.

[0111] Heavy chain variable region (VH) nucleic acids can be isolated from hybridoma and/or B cells using standard molecular biology techniques known in the art (Sambrook, et al. 1989. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y.; Ausubel, et al. 1995. Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons). Once the VH nucleic acid sequence has been determined, the deduced amino acid sequence can be obtained and compared to other human VH sequences to identify a group of related VH sequences that have a similar sequence. Related VH sequences can be obtained using antibody databases available to those of skill in the art, *e.g.*, The International ImMunoGeneTics Information System® (IMGT®). This comparison may be performed by alignment of the sequences accomplished either by eye or, alternatively, electronically by employing an alignment program (*e.g.*, CLUSTAL). In this comparison, the complementary determining regions (CDRs) and framework regions (FRs) are identified. CDR and FR residues are determined according to a standard sequence definition (*e.g.*, Kabat et al. 1987, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda Md.; Chothia and Lesk, 1987. J. Mol Biol. 196:901-917). Those skilled in the art will appreciate that there may occasionally exist discrepancies in methods of numbering and determining the CDR and FR regions of an immunoglobulin heavy chain sequence. In such cases, the structural definition is preferred, however, the residues identified by the sequence definition method are considered important FR residues for determination of which framework residues to substitute based on a comparison of heavy chain sequences.

[0112] Once aligned, substitutable positions in the VH sequences are identified. If the identity of an amino acid at a position in the isolated VH sequence varies when compared to the other human VH sequences, that position is evaluated for the suitability of a substitution at that position of the isolated VH sequence. Therefore, any position in the isolated VH sequence that varies with the other related human VH sequence(s) to which it is being compared can potentially serve as a position that could be substituted with the amino acid at the corresponding position found in one or any of the other related human VH sequences. Positions that share identity with the other related human VH sequences, *i.e.*, those that do not demonstrate variability, are determined to be nonsubstitutable positions. In various instances, the above methods are employed to provide a consensus human heavy chain antibody sequence.

[0113] A humanized heavy chain antibody for the purposes described herein is an immunoglobulin heavy chain amino acid sequence variant or fragment thereof that is capable of binding to a predetermined antigen and that comprises a FR region having a substantially similar or an identical amino acid sequence as compared with a human FR amino acid sequence, and a CDR having a substantially similar or an identical amino acid sequence to a non-human CDR amino acid sequence. In general, a humanized heavy chain antibody has one or more amino acid residues that are derived from a non-human source. Such residues are typically derived from a heavy chain variable domain. Further, these

residues may have associated characteristics such as, for example, affinity and/or specificity as well as other desirable biological activity associated with antibody function.

[0114] In various embodiments, the humanized heavy chain antibody comprises substantially all of at least one, and in other embodiments at least two, VH domains in which all or substantially all of the CDR regions correspond to those of a non-human VH domain and all or substantially all of the FR regions are those of a human VH domain sequence. The humanized heavy chain antibody will comprise a unique immunoglobulin constant region (Fc), that in one embodiment lacks at least the CH1 domain, and in one embodiment also lacks the hinge region of a human Fc. In one embodiment, the heavy chain antibody will not comprise a light chain and will comprise the CH2 and CH3 regions of an immunoglobulin G (IgG) heavy chain constant region. In one embodiment, the constant region of the heavy chain antibody will include the hinge, CH2 and CH3 regions of the IgG heavy chain Fc. In one embodiment, the constant region of the heavy chain antibody will include a CH1 region of an IgM.

[0115] The humanized heavy chain antibody will be selected from any class of IgGs, including IgG1, IgG2, IgG3 and IgG4. In various embodiments, the constant region may comprise sequences from more than one class of IgG, and selecting particular constant regions to optimize desired effector functions is within the ordinary skill in the art.

[0116] In general, the heavy chain FR and heavy chain CDR regions of the humanized heavy chain antibody need not correspond precisely to the parental sequences, e.g., the non-human heavy chain CDR or the human heavy chain FRs may be altered by substitution, insertion or deletion of at least one residue so that the heavy chain CDR or heavy chain FR residue at a given site does not correspond to either the human heavy chain FR sequence or the non-human heavy chain CDR sequence. Such mutations, however, will not be extensive. In one embodiment, at least 75% of the humanized heavy chain antibody residues will correspond to those of the parental heavy chain FR and heavy chain CDR sequences, in another embodiment 90%, and in another embodiment greater than 95%.

[0117] Humanized heavy chain antibodies as disclosed herein are, in one embodiment, prepared by a process of analyzing parental sequences and various conceptual humanized composite sequences *in silico*, using computer programs available and known to those skilled in the art. Sequence modifications to make humanized versions and/or for changing characteristics such as immunogenicity, affinity, etc. are made employing methods known in the art (e.g., US 5,565,332 Hoogenboom et al.; US 5,639,641 Pedersen et al.; US 5,766,886 Studnicka et al.; US 5,859,205 Adair et al.; US 6,054,297 Carter et al.; US 6,407,213 Carter et al.; US 6,639,055 Carter et al.; US 6,849,425 Huse et al.; US 6,881,557 Foote; US 7,098,006 Gorman et al.; US 7,175,996 Watkins et al.; US 7,235,643 Nicolaides et al.; US 7,393,648 Rother et al.; US 7,462,697 Couto et al.).

[0118] In various instances, desired substitutions to a parental heavy chain antibody sequence to make a variant of a parental heavy chain antibody are those that in one embodiment maintain, or in another embodiment increase, the antigen binding activity of the parental heavy chain antibody. In general, a heavy chain antibody variant of a parental heavy chain antibody has an antigen binding affinity that is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% (e.g., at least 150%, at least 200%, at least 500%, at least 1000%, or up to at least 10,000%) of the binding affinity of the parental heavy chain antibody to a particular antigen. In some embodiments, a variant heavy chain antibody will comprise a single substitution as compared to a parental heavy chain antibody. However, in other instances, several amino acids, e.g., up to about 5 or 10 or more, are substituted as compared to the parental heavy chain antibody sequence that are derived from other human heavy chain sequences that share identity at a given position. Substitutions in one embodiment are conservative (i.e., an amino acid sharing similar properties to the residue to be replaced), and in another embodiment non-conservative (i.e., an amino acid sharing different properties to the residue to be replaced). In various instances, the resultant variant heavy chain antibody is tested to confirm that the desired binding affinity and/or specificity has not been significantly decreased by the replacement residues. In some embodiments, an improved variant heavy chain antibody is produced by the substitution of amino acids from a different human heavy chain sequence.

[0119] Naturally occurring heavy chain antibodies (e.g., found in camelids) have been demonstrated to contain unique amino acid residues at positions corresponding to the interface between heavy and light chain variable regions in traditional antibody molecules (i.e., two heavy chains and two light chains). These interface residues are known to affect the proximity or orientation of the two chains relative to one another in traditional antibodies. Although these natural heavy chain antibodies are known to contain replacement of residues that correlate with the absence of light chain variable regions, they retain the residues at other positions in the sequence as compared to traditional antibodies for preserving the characteristic immunoglobulin fold. The substitutions found in natural heavy chain antibodies are L11S, V37F, G44E, L45R or L45C, W47G and additional cysteine residues that contribute to a disulfide bond between the CDR1 and CDR3 of the heavy chain variable region. In some instances, heavy chain antibodies may retain the residue of the parental antibody at these positions. In other instances, the parental antibody may display mutations at these positions that are associated with the residues in natural heavy chain antibodies. In some instances, it may be desirable to retain the same residue as is found in the parental heavy chain antibody at at least one of these positions or, in one instance, all of these positions when making a humanized heavy chain antibody derived from an isolated VH sequence from a genetically modified mouse as described herein. In various instances, a person of skill in the art will understand

that these interface residues are not reasonably expected to be involved in interchain interactions in heavy chain antibodies made by the genetically modified mouse as described herein.

Making Genetically Modified Animals

[0120] Genetic modifications for making an animal that expresses a heavy chain antibody are conveniently described by using the mouse as an illustration. A genetically modified mouse according to the invention can be made in a variety of ways, particular embodiments of which are discussed below.

[0121] A schematic illustration (not to scale) of an IgG1 locus is provided in Figure 1 (top) to show CH domain arrangement at the IgG1 locus. As illustrated, domains CH1, CH2, and CH3 and the hinge region are present in readily identifiable spans of nucleotide downstream of a switch region.

[0122] A genetically modified mouse lacking a nucleotide sequence encoding a CH1 domain of an IgG1 but containing a hinge region can be made by any method known in the art. For example, a targeting vector can be made that replaces the IgG1 gene with a truncated IgG1 lacking a CH1 domain but containing the hinge. Figure 2 illustrates a mouse genome (top) targeted by a targeting construct having a 5' (with respect to the direction of transcription of the genomic IgG1 gene) homology arm containing sequence upstream of the endogenous CH1 domain, followed by nucleotide sequences that encode an IgG1 hinge, an IgG1 CH2 domain, an IgG1 CH3 domain, a drug selection cassette (e.g., a loxed resistance gene), and an IgG1 transmembrane domain, and a 3' homology arm containing sequence 3' with respect to the transmembrane domain. Upon homologous recombination at the locus and removal of the drug selection cassette (e.g., by Cre treatment), the endogenous IgG1 is replaced by an IgG1 that lacks a CH1 domain (bottom of Figure 2; lox site not shown). Figure 1 (IgG1 Δ CH1, middle) shows the structure of the resulting locus, which will express an IgG1 having a J region sequence fused to the hinge sequence.

[0123] A genetically modified mouse lacking a nucleotide sequence encoding a CH1 domain of an IgG1 and lacking a nucleotide sequence encoding a hinge region can be made by any method known in the art. For example, a targeting vector can be made that replaces the IgG1 gene with a truncated IgG1 lacking a sequence encoding a CH1 domain and lacking a sequence encoding the hinge region. Figure 3 illustrates a mouse genome (top) targeted by a targeting construct having a 5' (with respect to the direction of transcription of the genomic IgG1 gene) homology arm containing sequence upstream of the endogenous CH1 domain, followed by nucleotide sequences that encode an IgG1 CH2 domain, an IgG1 CH3 domain, a drug selection cassette (e.g., a loxed resistance gene), and an IgG1 transmembrane domain, and a 3' homology arm containing sequence 3' with respect to the transmembrane domain. Upon homologous recombination at the locus and removal of the drug selection cassette (e.g., by Cre treatment), the endogenous IgG1 gene is replaced by an IgG1 gene that lacks a sequence encoding a CH1 domain (bottom of Figure 3; lox site not shown). Figure 1 (IgG1 Δ CH1- Δ hinge, bottom) shows the structure of the resulting locus, which will express an IgG1 having a J region sequence fused to the CH2 domain.

[0124] A genetically modified mouse lacking an IgG1 CH1 sequence (IgG1 Δ CH1), or lacking an IgG1 CH1 sequence and lacking a hinge (IgG1 Δ CH1- Δ hinge), can be further modified to favor usage of the modified IgG1 isotype by deleting one or more other IgG isotypes, e.g., by deleting or functionally disabling sequences encoding IgG2b and IgG2a. For example, a targeting construct is made having a 5' homology arm containing sequence upstream of the endogenous hinge region sequence (or upstream of the endogenous CH1 domain sequence), sequences that encode the IgG1 CH2 and CH3 domains, a drug selection cassette followed by a sequence encoding the IgG1 transmembrane domain, followed by another drug selection cassette if desired. Upon homologous recombination at the locus and removal of the drug selection cassette(s) (e.g., by Cre treatment), the endogenous heavy chain constant locus contains only two IgG genes: an endogenous IgG3 and the IgG1 Δ CH1 (see Figure 4, bottom; recombinase site(s) not shown; see Figure 6, bottom) or IgG1 Δ CH1- Δ hinge (see Figure 5, bottom; recombinase site(s) not shown; see Figure 6, bottom).

[0125] An IgG1 expressed in a genetically modified mouse having an IgG1 Δ CH1- Δ hinge or an IgG1 Δ CH1 Δ IgG2a Δ IgG2b allele will have a structure as shown on the right panel of Figure 10, i.e., the VH domain will be fused to the CH2 domain. The left panel of Figure 10 provides, for comparison, a wild-type IgG1 antibody, showing its CH1 domain linked via a hinge region to the CH2 domain, and linked by disulfide linkage to the light chain constant domain CL. In contrast, the antibody made by the genetically modified mouse lacks the hinge and CH1 domains and thus lacks any CL domain.

[0126] Genetically modified mice as described above, and others, are made by introducing a suitable targeting construct into a suitable mouse ES cell (in one or more independent targetings), and positive clones comprising a marker or selection cassette of the targeting construct are identified and grown. Clones are then employed as donor ES cells in a host embryo under conditions suitable for making a chimeric mouse or a fully ES cell-derived mouse. The marker or selection cassette can be optionally removed, either at the ES cell stage or in the chimeric or ES cell-derived mouse, e.g., by employing a loxed cassette and breeding to a Cre-containing strain, or by electroporating the ES cell with a Cre expression vector.

[0127] A genetically modified mouse having an IgG1 Δ CH1- Δ hinge allele (heterozygous) was made in accordance with

an embodiment of the invention. Serum was isolated from the mouse and blotted in a Western (reducing conditions) using an anti-mouse IgG1 antibody to detect heavy chain. In contrast to a wild-type mouse, which displayed a band corresponding in size to a wild-type IgG1 heavy chain, the mouse genetically modified to contain the IgG1 Δ CH1- Δ hinge allele also expressed a heavy chain that reacted with anti-mouse IgG1 antibody that had the expected size of a heavy chain antibody consisting of the VH, CH2, and CH3 domains (see Figure 8).

EXAMPLES

Example 1: *In vitro* Expression of Heavy Chain Antibodies

[0128] Chimeric heavy chain constructs were made using molecular biology techniques (e.g., see Maniatis et al. 1982. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory) to fuse human variable regions with a murine IgG2b (mIgG2b) constant region. The human variable gene segment for each construct was a full-length human variable gene segment containing both exons (i.e., leader sequence plus mature sequence), identified from an hVR of an IgM isolated from a naive RAG mouse that contained a replacement of the endogenous mouse immunoglobulin heavy chain locus with three hVR gene segments, all hDH gene segments, and all hJH gene segments. The light chain of the IgM antibody was a mouse light chain.

[0129] Two versions of the mIgG2b sequence were used; one with and one without a CH1 domain. Several other constructs were also made to serve as transfection and expression controls. A first control construct was made using a cytokine receptor fused to the CH2 and CH3 domains of mouse IgG2a (mIgG2a) constant region (Control I). Two other controls were constructed by fusing a murine ROR signal sequence to a murine IgG2a sequence with and without CH1 domains (Control II and III, respectively).

[0130] Camelized versions of each human variable region were also made using PCR site-directed mutagenesis techniques (e.g., see Hutchinson et al. 1978. Mutagenesis at a specific position in a DNA sequence. J. Biol. Chem. 253(18):6551-60). Two specific primer sets were used for each variable region to create specific mutations within the human variable region sequence resulting in a human variable region sequence containing camel-like features. Primers L1 (SEQ ID NO:1) and HH1.2 mut BOT (SEQ ID NO:2) were used to amplify one product comprising the 5' half of the variable region while primers HH1.2 mut TOP (SEQ ID NO:3) and m18.3.1 (SEQ ID NO:4) were used to amplify the 3' half of the variable region. These products were purified and mixed together to serve as a template for a third PCR reaction using primers L1 and m18.3.1. The resulting camelized human variable region PCR product was cloned, purified and confirmed by sequencing.

[0131] The full length heavy chain constructs (variable and constant) were made by amplifying the human variable regions (camelized and non-camelized) and constant regions with primers containing restriction enzyme sites to allow for subsequent ligation together via cohesive ends. All full length heavy chain constructs were cloned into expression vectors, purified and confirmed again by sequencing. Table 1 sets forth each heavy chain construct, their SEQ ID NOs and a short description for each construct.

Table 1		
Construct	Description	SEQ ID NO (DNA/Protein)
hVR-mFc	Non-camelized human variable region fused to mouse IgG2b	5/6
hVR*-mFc	Camelized human variable region fused to mouse IgG2b	7/8
hVR-mFc Δ CH1	Non-camelized human variable region fused to mouse IgG2b lacking a CH1 domain	9/10
hVR*-mFc Δ CH1	Camelized human variable region fused to mouse IgG2b lacking a CH1 domain	11/12

[0132] Chimeric heavy chain constructs were transiently transfected into Chinese Hamster Ovary cells (CHO-K1) to analyze expression in the absence of immunoglobulin light chain. Supernatants and cell lysates were examined by Western blot to detect presence of heavy chain using horseradish peroxidase (HRP) conjugated anti-mouse IgG antibody (Promega) by chemilumescence. All the chimeric heavy chain constructs were transiently transfected six (6) independent times. A representative Western blot of the transfections is shown in Figure 7.

[0133] All chimeric heavy chain constructs, with and without the CH1 domain, as well as the control constructs, were detected in the cell lysate. Only constructs lacking a CH1 domain were observed in the supernatants (Figure 7, left). Control I and Control III (mouse Fc protein lacking a CH1 domain) were also detected (Figure 7), but mouse Fc protein containing a CH1 domain was not detected. Both non-camelized and camelized heavy chain constructs containing a

CH1 domain were not detected in the supernatant for any transfection (Figure 7, right). However, both non-camelized and camelized human heavy chain constructs lacking a CH1 domain were detected in the supernatant for all transfections. Together, the results establish that hVRs (normal or camelized) that lack a CH1 domain can be expressed and secreted from transiently transfected CHO cells in the absence of immunoglobulin light chain, whereas hVRs (normal or camelized) that contain a CH1 domain could not be secreted in the absence of light chain.

Example 2: Modification of the Mouse Heavy Chain IgG1 Constant Region

A. Preparation of a mouse IgG1-CH1-Hinge Targeting Vector (Figure 3)

[0134] A targeting construct for introducing a deletion of the CH1 and hinge regions of the mouse IgG1 constant domain for the C57BL/6 allele from an ES cell of a VELOCIMMUNE® mouse (described below) was constructed.

[0135] The targeting construct was made using VELOCIGENE® technology (see, e.g., US Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659) to modify the Bacterial Artificial Chromosome (BAC) BMQ 70p08. BMQ 70p08 BAC DNA was modified to delete the CH1 and hinge regions of the IgG1 constant domain while leaving the remainder of the IgG1 gene intact (e.g., CH2, CH3 and transmembrane exons).

[0136] Briefly, upstream and downstream homology arms were made employing primers m102 (SEQ ID NO:13) and m104 (SEQ ID NO:14) and m100 (SEQ ID NO:15) and m99 (SEQ ID NO:16), respectively. These homology arms were used to make a cassette that deleted the CH1 and hinge regions of the IgG1 constant domain while retaining the CH2, CH3 and transmembrane regions of the IgG1 constant domain (see, e.g., Figure 3). The targeting construct included a loxed hygromycin resistance gene positioned between the CH3 and transmembrane domain exons of the IgG1 gene. Genes upstream of the CH1 and hinge exons (e.g., IgG3, IgD, IgM) and downstream of the IgG1 transmembrane exon (e.g., IgG2b, IgG21, IgE, IgA, etc.) were unmodified by the targeting construct. Switch regions for all constant domains were unmodified by the targeting construct. The nucleotide sequence across the deletion included the following, which indicates a splice acceptor sequence that is present at the deletion point: TGACAGTGTA ATCACATATA CTTTTTCTTG T(AG)TCCCAGA AGTATCATC (SEQ ID NO:17). The deletion sequence comprises a splice acceptor (the AG contained within parentheses above) with pre-CH1 sequences 5' of the splice acceptor and CH2 exon sequences 3' of the splice acceptor.

B. Preparation of a mouse IgG1-CH1 Targeting Vector (Figure 2)

[0137] A second targeting construct for introducing a deletion of the CH1 of the mouse IgG1 constant domain for the 129/SvEvTac allele from an ES cell of a VELOCIMMUNE® mouse (described below) was constructed in a similar fashion as described in section A of this Example.

[0138] The targeting construct was made using VELOCIGENE® technology (see, e.g., US Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659) to modify the Bacterial Artificial Chromosome (BAC) BMQ 70p08. BMQ 70p08 BAC DNA was modified to delete the CH1 region of the IgG1 constant domain while leaving the remainder of the IgG1 gene intact (e.g., hinge, CH2, CH3 and transmembrane exons; see Figure 2).

[0139] The homology arms for the second targeting construct were the same as those for the CH1-Hinge targeting vector (as described above in section A of this Example). These homology arms were used to make a cassette that deleted the CH1 region of the IgG1 constant domain while retaining the hinge, CH2, CH3 and transmembrane regions of the IgG1 constant domain (see, e.g., Figure 2). The targeting construct included a loxed hygromycin resistance gene positioned between the CH3 and transmembrane domain exons of the IgG1 gene. Genes upstream of the CH1 exon (e.g., IgG3, IgD, IgM) and downstream of the IgG1 transmembrane exon (e.g., IgG2b, IgG21, IgE, IgA, etc.) were unmodified by the targeting construct. Switch regions for all constant domains were unmodified by the targeting construct. The nucleotide sequence across the deletion included the following, which indicates a splice acceptor sequence that is present at the deletion point: TGACAGTGTA ATCACATATA CTTTTTCTTG T(AG)TGCCCAG GGATTGTGGT TG-TAAGCCTT GCATATGTACAGGTAAGTCA GTAGGCCTTT CACCCTGACC C (SEQ ID NO:64). The deletion sequence comprises a splice acceptor (the AG contained within parentheses above) with pre-CH1 sequences 5' of the splice acceptor and hinge exon sequences 3' of the splice acceptor.

Example 3: Modification of the Mouse Heavy Chain Constant Region in ES Cells

A. Targeting Mouse ES Cells with an IgG1-CH1-Hinge Targeting Vector

[0140] A mouse ES cell was targeted with the targeting construct described above (i.e., a targeting construct introducing

a deletion of the CH1 and hinge regions of the IgG1 gene). The ES cell was from a VELOCIMMUNE® mouse that was a 50/50 mix of a 129 strain and a C57BL/6 strain, bearing genetic modifications that comprise replacement of mouse heavy and light chain variable region gene segments with unrearranged human heavy and light chain variable region gene segments. The 129 strain employed to cross with C57BL/6 is a strain that comprises a replacement of mouse heavy chain and light chain variable region gene segments with human heavy chain and light chain variable region gene segments.

[0141] The heterozygous VELOCIMMUNE® mice bear a single set of endogenous mouse heavy chain constant region genes from the 129 strain at one allele and a single set of endogenous mouse heavy chain constant region genes from the C57BL/6 strain at the other allele. The 129 heavy chain allele is contiguous with a locus of heavy chain variable region gene segments that are human heavy chain variable region gene segments that have replaced the endogenous mouse heavy chain variable region gene segments (*i.e.*, at the endogenous mouse locus). The BL/6 heavy chain allele is contiguous with wild-type mouse heavy chain variable region gene segments. The VELOCIMMUNE® mice also bear wild-type endogenous mouse light chain constant region genes. Thus, by targeting the 129 allele with a construct comprising an IgG, D, E, or A CH1 deletion a chimeric human/mouse heavy chain antibody could be produced, whereas by targeting the C57BL/6 allele with a similar construction, a fully mouse heavy chain antibody lacking a CH1 domain and lacking a hinge could be produced.

[0142] ES cells from the VELOCIMMUNE® mice described above were electroporated with linearized targeting vector of section A in Example 2 and selected for the presence of the hygromycin resistance gene.

B. Targeting Mouse ES Cells with an IgG1-CH1 Targeting Vector

[0143] In a similar fashion, a mouse ES cell was targeted with the CH1 targeting construct described in section B of Example 2 (see also Figure 2). The ES cell was from a VELOCIMMUNE® mouse that was a 50/50 mix of a 129/SvEvTac strain and a C57BL/6 strain, bearing genetic modifications that comprise replacement of mouse heavy and light chain variable region gene segments with unrearranged human heavy and light chain variable region gene segments. The 129/SvEvTac strain employed to cross with C57BL/6 is a strain that comprises a replacement of mouse heavy chain and light chain variable region gene segments with human heavy chain and light chain variable region gene segments.

[0144] The heterozygous VELOCIMMUNE® mice bear a single set of endogenous mouse heavy chain constant region genes from the 129/SvEvTac strain at one allele and a single set of endogenous mouse heavy chain constant region genes from the C57BL/6 strain at the other allele. The 129/SvEvTac heavy chain allele is contiguous with a locus of heavy chain variable region gene segments that are human heavy chain variable region gene segments that have replaced the endogenous mouse heavy chain variable region gene segments (*i.e.*, at the endogenous mouse locus). The BL/6 heavy chain allele is contiguous with wild-type mouse heavy chain variable region gene segments. The VELOCIMMUNE® mice also bear wild-type endogenous mouse light chain constant region genes. Thus, by targeting the 129/SvEvTac allele with a construct comprising an IgG, D, E, or A CH1 deletion a chimeric human/mouse heavy chain antibody could be produced, whereas by targeting the C57BL/6 allele with a similar construction, a fully mouse heavy chain antibody lacking a CH1 domain and lacking a hinge could be produced.

[0145] ES cells from the VELOCIMMUNE® mice described above were electroporated with linearized targeting vector, described in section B in Example 2, and selected for the presence of the hygromycin resistance gene.

Example 4: Generation of Mice Carrying a Modified IgG1 Constant Region

A. Mice Carrying an IgG1-CH1-Hinge Deletion

[0146] Targeted ES cells described above were used as donor ES cells and introduced into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (see, *e.g.*, US Pat. No. 7,294,754 and Poueymirou *et al.* (2007) F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses Nature Biotech. 25(1):91-99. VELOCIMICE® (F0 mice fully derived from the donor ES cell) bearing targeted C57BL/6 IgG1 alleles were identified by genotyping using a modification of allele assay (Valenzuela *et al.*, *supra*) that detected the presence of sequences positioned upstream and downstream of the deleted hinge and CH1 regions.

[0147] Mice genotyped for the IgG1 CH1 and hinge deletion (in the C57BL/6 allele, *i.e.*, the mouse allele) were bred to a Cre deleter mouse strain (see, *e.g.*, International Patent Application Publication No. WO 2009/114400) in order to remove the loxed hyg cassette downstream of the IgG1 CH3 exon and upstream of the IgG1 transmembrane exon, introduced by the targeting construct (see, *e.g.*, Figure 3). Pups were genotyped and a pup heterozygous for the IgG1 CH1 and hinge deletion was selected to examine IgG1 heavy chain expressed from the C57BL/6 allele in the pup's serum.

B. Mice Carrying an IgG1-CH1 Deletion

[0148] In a similar fashion, targeted ES cells carrying a deletion of the IgG1 CH1 region were used as donor ES cells and introduced into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (see, e.g., US Pat. No. 7,294,754 and Poueymou et al. (2007) F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses Nature Biotech. 25(1):91-99. VELOCIMICE® (F0 mice fully derived from the donor ES cell) bearing targeted 129SvEv/Tac alleles were identified by genotyping using a modification of allele assay (Valenzuela *et al.*, supra) that detected the presence of sequences positioned upstream and downstream of the deleted CH1 region.

[0149] Mice genotyped for the IgG1 CH1 deletion (in the 129/SvEvTac allele, *i.e.*, the human allele) were bred to a Cre deleter mouse strain (see, e.g., International Patent Application Publication No. WO 2009/114400) in order to remove the loxed hyg cassette downstream of the IgG1 CH3 exon and upstream of the IgG1 transmembrane exon, introduced by the targeting construct (see, e.g., Figure 2). Pups were genotyped and a pup homozygous for the IgG1 CH1 deletion was selected to examine modified IgG1 heavy chain expression.

Example 5: Heavy Chain Antibodies from Mice Carrying a Modified IgG1 Gene

A. IgG1- Δ CH1- Δ Hinge Mice

[0150] A mouse pup identified above as containing the CH1 and hinge deletion, and a wild-type pup, were bled and sera from the bled mice were prepared for Western blotting to identify any expressed IgG in the sera using an anti-mIgG1 antibody. Briefly, 10 μ L of a 1:100 dilution of mouse sera was used in reducing SDS-PAGE, and the gel was transferred to a PVDF membrane. The blot was blocked overnight with 5% nonfat milk in Tris-Buffered Saline with 0.05% Tween-20 (TBST; Sigma), washed 4 times for 5 minutes per wash with TBST, and then exposed to primary antibody

(goat anti-mIgG1 conjugated to HRP, Southern Biotech) diluted 1:1,000 in 1 % nonfat milk in TBST for two hours at room temperature. The blot was washed 6 times for 5 minutes per wash. The blot was developed for 5 minutes with SUPERSIGNAL™ West Pico Chemiluminescent Substrate (Thermo Scientific) and then exposed to film for 1 minute.

[0151] Serum from the VELOCIMOUSE® (50% wild-type BL/6; 50% Δ CH1- Δ Hinge BL/6) derived from the targeted donor ES cell revealed a mixture of bands: one band of about 57.5 kD, the expected size for a wild-type IgG, and one band at about 45 kD, the expected size for an IgG lacking a CH1 domain and a hinge (Figure 8). The results are consistent with the VELOCIMOUSE® expressing a normal mouse heavy chain from the wild-type BL/6 allele and a Δ CH1/ Δ hinge mouse heavy chain from its Δ CH1- Δ hinge BL/6 allele. This result establishes that genetically modified mice bearing a functional IgM gene and an IgG gene that lacks a CH1 domain and a hinge domain are capable of expressing heavy chain antibodies in serum.

B. IgG1- Δ CH1 Mice

[0152] In a similar fashion, mouse pups homozygous for the CH1 deletion, and wild-type pups, were bled. Plasma and serum (for five homozygotes; two wild-type) from the bled mice were prepared for Western blotting to identify any expressed IgG in the sera using an anti-mIgG1 antibody (described above). Western blots of serum and plasma from mice homozygous for the IgG1- Δ CH1 deletion revealed a mixture of bands: one band of about 45 kD, the expected size for a single chain IgG1 lacking a CH1 domain, and one band at about 75 kD, the expected size for a dimer IgG lacking a CH1 domain (data not shown). The results are consistent with the homozygous VELOCIMICE® expressing an IgG1- Δ CH1 heavy chain from either one or both heavy chain loci. This result establishes that genetically modified mice bearing a functional IgM gene and an IgG gene that lacks a CH1 domain are capable of expressing heavy chain antibodies in the peripheral lymphocyte compartment of the animals' immune system.

Example 6: Characterization of Mice Homozygous for IgG1-CH1-Hinge Deletion

[0153] VELOCIMICE® heterozygous for the CH1-hinge deletion were bred together to obtain mice homozygous for the deletion. Four mouse pups were identified as homozygous for IgG1 Δ CH1- Δ hinge. These four mice and a wild-type mouse were bled and sera from the bled mice were prepared for Western blotting to identify any expressed IgG in the sera using an anti-mIgG1 antibody (as described above). Figure 9 shows the film developed from the PVDF-membrane used in this experiment. Serum was diluted 1:5 and 1:10 and 10 μ L of each dilution was loaded onto the gel side-by-side for each mouse. On the top portion of the gel images, the lanes are labeled for each mouse as well as IgG1 (1) and IgG2a (2a) controls.

[0154] Serum from the wild-type mouse showed an expected pattern for a wild-type mouse that expresses normal antibodies comprising two heavy chains and two light chains (approximately 150 kD). All four mice (homozygous for

IgG1 Δ CH1- Δ hinge) each showed a mixture of bands: one band of about 150 kD, the expected size for a wild-type IgG other than IgG1 (e.g., IgG2a, IgG2b or IgG3), and one band at about 45 kD, the expected size for an IgG lacking a CH1 domain and a hinge (Figure 9). These results are consistent with the mice expressing an IgG1 heavy chain antibody lacking a CH1 domain and a hinge region and lacking a light chain. This result further establishes that genetically modified mice bearing a functional IgM gene and an IgG gene that lacks a CH1 domain and a hinge region are capable of expressing heavy chain antibodies in serum.

[0155] In another experiment, serum expression of IgG was determined from mice homozygous for the IgG1 Δ CH1- Δ hinge using an ELISA assay. Briefly, antibodies specific for either mIgG1 or mIgG2b (Pharmingen) were separately diluted and 100 μ L/well was coated onto plates at 2 μ g/mL in 1 x PBS (Irvine Scientific) and incubated at 4°C overnight. The following day the plates were washed four times with PBS with 0.05% Tween-20 (PBST; Sigma). After the fourth wash, plates were blocked with 250 μ L/well of PBST with 5% BSA (Sigma) and incubated at room temperature for one hour. Serum and standards were serially diluted (dilution factor of 0.316) in PBST in 0.5% BSA down the plate (from top to bottom) at a starting concentration of 400 ng/mL (mIgG1) or 600 ng/mL (mIgG2b). After blocking, the plates were washed again four times with PBST. Following the fourth wash, 100 μ L of serum or standard was added to the plates and incubated for one hour at room temperature. The plates were again washed four times with PBST. Following the washes, 100 μ L of a biotinylated detection antibody (10 ng/mL of rat anti-mIgG1 or 250 ng/mL of anti-mIgG2b; Pharmingen) was added to the plates and incubated for one hour at room temperature. The plates were again washed as described above. Following the wash, 100 μ L/well of a 1:20,000 dilution of horseradish peroxidase conjugated to streptavidin (HRP-SA) in PBST was added to the plates and the plates were incubated for 30 minutes at room temperature. The plates were then washed six times with PBST, after which 100 μ L/well of a 1:1 dilution of Substrate A and B (BD OPTIA™; BD Biosciences) was added and the plates were maintained in the dark. The reaction was developed in the dark and stopped as desired (approx. 15 minutes) with 1 N phosphoric acid. Stopped reactions were read on a Wallac 1420 Work Station VICTOR™ Plate Reader at an absorption wavelength of 450 nm (1.0 sec/reading) and the results plotted on graphs (Figure 11).

[0156] Serum from wild-type mice showed normal levels of IgG1 and IgG2b. Mice homozygous for IgG1 Δ CH1- Δ hinge were capable of expressing an IgG1 lacking a CH1 domain and a hinge region in the periphery (serum; left side of Figure 11). Further, serum levels of other IgG isotypes (e.g., IgG2b) were not noticeably reduced from wild-type levels (right side of Figure 11). This result further establishes that genetically modified mice bearing a functional IgM gene and an IgG gene that lacks a CH1 domain and a hinge region are capable of expressing a modified IgG1 isotype (i.e., lacking a CH1 domain and a hinge) that can be detected in serum.

Example 7: Analysis of V-D-J Rearrangements in IgG1 Modified Mice

A. Mice Homozygous for an IgG1-CH1-Hinge Deletion

[0157] Mice homozygous for the IgG1 Δ CH1- Δ hinge modification were analyzed for V-D-J recombination and heavy chain gene usage by reverse-transcriptase polymerase chain reaction (RT-PCR) using RNA isolated from splenocytes.

[0158] Briefly, spleens were harvested and perfused with 10 mL RPMI-1640 (Sigma) with 5% HI-FBS in sterile disposable bags. Each bag containing a single spleen was then placed in a STOMACHER™ (Seward) and homogenized at a medium setting for 30 seconds. Homogenized spleens were filtered using a 0.7 μ m cell strainer and then pelleted with a centrifuge (1000 rpm for 10 minutes) and red blood cells (RBCs) were lysed in BD PHARM LYSER™ (BD Biosciences) for three minutes. Splenocytes were diluted with RPMI-1640 and centrifuged again followed by resuspension in 1 mL of PBS (Irvine Scientific). RNA was isolated from pelleted splenocytes using standard techniques known in the art.

[0159] RT-PCR was performed on splenocyte RNA using a set of degenerate primers specific for mouse heavy chain variable region (VH) gene segments (Novagen) and a mouse IgG1 CH2 primer (CGATGGGGGC AGGGAAAGCT GCAC; SEQ ID NO:40). PCR products were gel-purified and cloned into pCR2.1-TOPO TA (Invitrogen) and sequenced with M13 Forward (GTAAACGAC GGCCAG; SEQ ID NO:41) and M13 Reverse (CAGGAAACAG CTATGAC; SEQ ID NO:42) primers located within the vector sequence at positions flanking the cloning site. Nineteen clones were sequenced to determine heavy chain gene usage and sequence of the junction of the rearranged VH and the CH2 of the IgG1 constant region (Table 2).

Table 2			
Heavy Chain Gene Usage			
Clone	V _H	D _H	J _H
B1	1-58	3-2	2

(continued)

	Table 2		
	Heavy Chain Gene Usage		
Clone	V _H	D _H	J _H
B2	1-26	4-1	1
B3	1-50	2-14	2
B4	1-58	3-2	2
B5	14-2	4-1	4
D2	3-6	1-1	4
D5	14-1	3-3	2
D6	14-2	4-1	3
D7	3-6	1-1	4
E2	7-1	3-1	4
E3	1-50	2-14	2
E4	1-50	2-14	2
E7	1-50	2-14	2
E8	1-72	1-1	4
E10	1-42	1-1	1
F6	5-6	1-1	1
F7	5-6	1-1	1
F8	5-6	1-1	1
F10	5-6	1-1	1

[0160] Figure 12 shows the sequence alignment of the V_H domains rearranged to the CH₂ of the IgG1 constant region for eleven of the nineteen RT-PCR clones. The sequences shown in Figure 12 illustrate unique rearrangements involving different mouse heavy chain V, D and J gene segments and mouse IgG1 devoid of CH₁ and hinge regions. Mice homozygous for a deletion of the CH₁ and hinge regions of the endogenous IgG1 constant region gene were able to produce heavy chains containing mouse V_H domains operably linked to a CH₂-CH₃ region from a mouse IgG1 constant region devoid of CH₁ and hinge regions and produce B cells that expressed mouse IgG1 heavy chains devoid of CH₁ and hinge regions and lacking a light chain (Figures 8 and 9). These rearrangements demonstrate that the modified loci were able to independently rearrange mouse heavy chain gene segments in multiple, independent B cells in these mice to produce heavy chain antibodies that are similar to those normally found in camels. Further, this Example demonstrates that the deletion of the endogenous IgG1 CH₁ and hinge regions did not render the locus inoperable or prevent recombination involving the modified IgG1 constant region. These mice made functional heavy chain antibodies containing an IgG1 devoid of CH₁ and hinge regions as part of the endogenous repertoire without any detectable defect in B cell development.

B. Mice Homozygous for an IgG1-CH1 Deletion

[0161] In a similar fashion, mice homozygous for the IgG1 Δ CH₁ modification were analyzed for V-D-J recombination and human heavy chain gene usage by reverse-transcriptase polymerase chain reaction (RT-PCR) using RNA isolated from splenocytes.

[0162] Briefly, spleens were isolated from two homozygous IgG1- Δ CH₁ mice as described above in section A of this Example. CD19⁺ B cells were isolated using magnetic cell sorting (MACS, Miltenyi Biotec) from pooled splenocytes. RNA was extracted from the sorted CD19⁺ B cells using Qiagen ALLPREP™ DNA/RNA mini kit (Qiagen). First-strand cDNA was synthesized with SUPERScript™ III Reverse Transcriptase and Oligo (dT)20 primers (Invitrogen). The

cDNA was then used as a template for PCR performed with a 3' mouse IgG1 hinge specific primer and 5' degenerate primers designed to bind human heavy variable leader sequences (Table 3). PCR products were cloned into pCR2.1 TOPO™ TA vector (Invitrogen) and sequenced with M13 Forward and M13 Reverse primers (as described above in section A of this Example).

Table 3		
Primer	Sequence (5'-3')	SEQ ID NO:
hVHL-1	TCACCATGGA CTGSACCTGG A	43
hVHL-2	CCATGGACAC ACTTTGYTCC AC	44
hVHL-3	TCACCATGGA GTTTGGGCTG AGC	45
hVHL-4	AGAACATGAA ACAYCTGTGG TTCTT	46
hVHL-5	ATGGGGTCAA CCGCCATCCT	47
hVHL-6	ACAATGTCTG TCTCCTTCCT CAT	48
3' mIgG1 Hinge	GCAAGGCTTA CAACCACAAT C	49

[0163] To determine heavy chain gene usage in mice homozygous for IgG1 Δ CH1, twenty-eight RT-PCR clones were sequenced. Within these clones, seven unique rearrangements of human V, D and J gene segments were observed (Table 4).

Table 4			
Heavy Chain Gene Usage			
Clone	V _H	D _H	J _H
A2	1-69	6-19	6
A5	1-69	6-7	4
A8	1-8	4-4	4
C2	1-18	6-6	2
C4	1-18	3-16	6
D9	1-18	6-6	4
H8	1-18	1-7	4

[0164] Figure 13 shows the sequence alignment of the VH domains rearranged to the hinge-CH2-CH3 of the IgG1 constant region for the seven rearrangements shown in Table 4. The sequences shown in Figure 13 illustrate unique rearrangements involving different human heavy chain V, D and J gene segments and mouse IgG1 devoid of the CH1 region. Mice homozygous for a deletion of the CH1 region of the endogenous IgG1 constant region gene were able to produce heavy chains containing human VH domains operably linked to a hinge-CH2-CH3 region from a mouse IgG1 constant region devoid of CH1 and produce B cells that expressed mouse IgG1 heavy chains devoid of CH1 regions and lacking a light chain (data not shown). These rearrangements demonstrate that either one or both modified loci (IgG1 Δ CH1- Δ hinge and IgG1 Δ CH1) were able to independently rearrange heavy chain gene segments (mouse and human) in multiple, independent B cells in these mice to produce heavy chain antibodies that are similar to those normally found in camels. Further, this Example demonstrates that the deletion of the endogenous IgG1 CH1 did not render the locus inoperable or prevent recombination involving human heavy chain V, D and J gene segments and the modified mouse IgG1 constant region. These mice made functional heavy chain antibodies containing human heavy chain V domains and a mouse IgG1 devoid of CH1 as part of the endogenous repertoire without any detectable defect in B cell development.

SEQUENCE LISTING

[0165]

5 <110> Regeneron Pharmaceuticals, Inc.

 <120> MICE THAT MAKE HEAVY CHAIN ANTIBODIES

 <130> 0761A-WO

10 <140> To be assigned

 <141> 2010-12-10

 <150> 61/285,250

15 <151> 2009-12-10

 <160> 64

 <170> Fast SEQ for Windows Version 4.0

20 <210> 1

 <211> 21

 <212> DNA

 <213> Artificial Sequence

25 <220>

 <223> synthetic

 <400> 1

30 tcaccatgga ctggacctgg a 21

 <210> 2

 <211> 40

 <212> DNA

35 <213> Artificial Sequence

 <220>

 <223> synthetic

40 <400> 2

 cccatcaact cacactcttg tccaggggcc tgcgaaacc 40

 <210> 3

 <211> 40

45 <212> DNA

 <213> Artificial Sequence

 <220>

 <223> synthetic

50 <400> 3

 ctggtttcga caggcccctg gacaagagtg tgagttgatg 40

 <210> 4

55 <211> 33

 <212> DNA

 <213> Artificial Sequence

<220>

<223> synthetic

<400> 4

5 acgttccgga tgaggagacg gtgaccaggg ttc 33

<210> 5

<211> 1449

<212> DNA

10 <213> Artificial Sequence

<220>

<223> synthetic

15 <400> 5

atggactgga cctggaggat ccttttcttg gtggcagcag ccacaggagc ccactcccag 60
 gtgcagctgg tgcagtctgg ggctgagggt aagaagcctg gggcctcagt gaaggtctcc 120
 20 tgcaaggctt ctggatacac cttcacccggc tactatatgc actgggtgcg acaggcccct 180
 ggacaagggc ttgagtggat gggatggatc aaccctaaca gtggtggcac aaactatgca 240
 cagaagtttc agggcagggg caccatgacc ggggacacgt ccatcagcac agcctacatg 300
 gagctgagca ggctgagatc tgacgacacg gccgtgtatt actgtgcgag aggctcctta 360
 tattgtacta atggtgtatg ctttgactac tggggccagg gaaccctggg caccgtctcc 420
 25 tcaaagcttt ccaaaacaac acccccatca gtctatccac tggcccctgg gtgtggagat 480
 acaactgggt cctccgtgac tctgggatgc ctggtcaagg gctacttccc tgagtcagtg 540
 actgtgaact ggaactctgg atccctgtcc agcagtgtgc acaccttccc agctctcctg 600
 cagtctggac totacactat gagcagctca gtgactgtcc cctccagcac ttggccaagt 660
 cagaccgtca cctgcagcgt tgctcaccca gccagcagca ccacggtgga caaaaaactt 720
 gtccggagcg agcccagcgg gcccatctca acaatcaacc cctgtcctcc atgcaaggag 780
 30 tgtcacaaat gccagctcc taacctcgag ggtggacat ccgtcttcat cttccctcca 840
 aatatcaagg atgtactcat gatctccctg acaccaagg tcacgtgtgt ggtggtggat 900
 gtgagcgagg atgaccaga cgtccagatc agctggtttg tgaacaacgt ggaagtacac 960
 acagctcaga cacaaaccca tagagaggat tacaacagta ctatccgggt ggtcagcacc 1020
 ctccccatcc agcaccagga ctggatgagt ggcaaggagt tcaaagtcaa ggtcaacaac 1080
 35 aaagacctcc catcacccat cgagagaacc atctcaaaaa ttaaagggct agtcagagct 1140
 ccacaagtat acatcttgcc gccaccagca gagcagttgt ccaggaaaga tgtcagtcctc 1200
 acttgccctgg tcgtgggctt caaccctgga gacatcagtg tggagtggac cagcaatggg 1260
 catacagagg agaactacaa ggacacccgca ccagtcctgg actctgacgg ttcttacttc 1320
 atatatagca agctcaatat gaaaaacaagc aagtgggaga aaacagattc cttctcatgc 1380
 40 aacgtgagac acgaggggtct gaaaaattac tacctgaaga agaccatctc ccggtctccg 1440
 ggtaaatga 1449

<210> 6

<211> 482

45 <212> PRT

<213> Artificial Sequence

<220>

<223> synthetic

50 <400> 6

55

EP 2 509 409 B1

	Met	Asp	Trp	Thr	Trp	Arg	Ile	Leu	Phe	Leu	Val	Ala	Ala	Ala	Thr	Gly
	1				5					10					15	
	Ala	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
				20					25					30		
5	Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe
			35					40					45			
	Thr	Gly	Tyr	Tyr	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu
	50						55					60				
	Glu	Trp	Met	Gly	Trp	Ile	Asn	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Tyr	Ala
10	65					70					75				80	
	Gln	Lys	Phe	Gln	Gly	Arg	Val	Thr	Met	Thr	Gly	Asp	Thr	Ser	Ile	Ser
				85						90				95		
	Thr	Ala	Tyr	Met	Glu	Leu	Ser	Arg	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val
				100					105					110		
15																
20																
25																
30																
35																
40																
45																
50																
55																

EP 2 509 409 B1

	Tyr	Tyr	Cys	Ala	Arg	Gly	Ser	Leu	Tyr	Cys	Thr	Asn	Gly	Val	Cys	Phe
			115					120					125			
	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Lys	Leu	Ser
	130						135					140				
5	Lys	Thr	Thr	Pro	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Gly	Cys	Gly	Asp
	145					150					155					160
	Thr	Thr	Gly	Ser	Ser	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys	Gly	Tyr	Phe
					165					170					175	
	Pro	Glu	Ser	Val	Thr	Val	Thr	Trp	Asn	Ser	Gly	Ser	Leu	Ser	Ser	Ser
10				180					185					190		
	Val	His	Thr	Phe	Pro	Ala	Leu	Leu	Gln	Ser	Gly	Leu	Tyr	Thr	Met	Ser
		195					200						205			
	Ser	Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Ser	Gln	Thr	Val	Thr
	210						215					220				
15	Cys	Ser	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Thr	Val	Asp	Lys	Lys	Leu
	225					230					235					240
	Val	Arg	Ser	Glu	Pro	Ser	Gly	Pro	Ile	Ser	Thr	Ile	Asn	Pro	Cys	Pro
				245					250						255	
	Pro	Cys	Lys	Glu	Cys	His	Lys	Cys	Pro	Ala	Pro	Asn	Leu	Glu	Gly	Gly
20				260					265					270		
	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Asn	Ile	Lys	Asp	Val	Leu	Met	Ile
		275						280					285			
	Ser	Leu	Thr	Pro	Lys	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Glu	Asp
	290						295					300				
25	Asp	Pro	Asp	Val	Gln	Ile	Ser	Trp	Phe	Val	Asn	Asn	Val	Glu	Val	His
	305					310					315					320
	Thr	Ala	Gln	Thr	Gln	Thr	His	Arg	Glu	Asp	Tyr	Asn	Ser	Thr	Ile	Arg
				325						330					335	
	Val	Val	Ser	Thr	Leu	Pro	Ile	Gln	His	Gln	Asp	Trp	Met	Ser	Gly	Lys
				340					345					350		
30	Glu	Phe	Lys	Cys	Lys	Val	Asn	Asn	Lys	Asp	Leu	Pro	Ser	Pro	Ile	Glu
		355						360					365			
	Arg	Thr	Ile	Ser	Lys	Ile	Lys	Gly	Leu	Val	Arg	Ala	Pro	Gln	Val	Tyr
	370						375					380				
	Ile	Leu	Pro	Pro	Pro	Ala	Glu	Gln	Leu	Ser	Arg	Lys	Asp	Val	Ser	Leu
35	385					390					395					400
	Thr	Cys	Leu	Val	Val	Gly	Phe	Asn	Pro	Gly	Asp	Ile	Ser	Val	Glu	Trp
				405						410					415	
	Thr	Ser	Asn	Gly	His	Thr	Glu	Glu	Asn	Tyr	Lys	Asp	Thr	Ala	Pro	Val
				420					425					430		
40	Leu	Asp	Ser	Asp	Gly	Ser	Tyr	Phe	Ile	Tyr	Ser	Lys	Leu	Asn	Met	Lys
		435						440					445			
	Thr	Ser	Lys	Trp	Glu	Lys	Thr	Asp	Ser	Phe	Ser	Cys	Asn	Val	Arg	His
		450					455					460				
	Glu	Gly	Leu	Lys	Asn	Tyr	Tyr	Leu	Lys	Lys	Thr	Ile	Ser	Arg	Ser	Pro
45	465					470					475					480
	Gly	Lys														

<210> 7

<211> 1449

50 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

55

<400> 7

EP 2 509 409 B1

atggactgga cctggaggat ccttttcttg gtggcagcag ccacaggagc cactcccag 60
gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt gaaggtctcc 120

5 tgcaaggctt ctggatacac cttcaccggc tactatatgc actggtttcg acaggcccct 180
ggacaagagt gtgagttgat gggatggatc aaccctaaca gtggtggcac aaactatgca 240
cagaagtttc agggcagggt caccatgacc ggggacacgt ccacagcac agcctacatg 300
gagctgagca ggctgagatc tgacgacacg gccgtgtatt actgtgcgag aggctcctta 360
10 tattgtacta atgggtgtatg ctttgactac tggggccagg gaaccctggg caccgtctcc 420
tcaaagcttt ccaaaacaac acccccatca gtctatccac tggcccctgg gtgtggagat 480
acaactgggt cctccgtgac tctgggatgc ctggtcaagg gctacttccc tgagtcagtg 540
actgtgactt ggaactctgg atccctgtcc agcagtgtgc acaccttccc agctctcctg 600
cagtcctggac tctacactat gagcagctca gtgactgtcc cctccagcac ttggccaagt 660
cagaccgtca cctgcagcgt tgctcaccga gccagcagca ccacggtgga caaaaaactt 720
15 gtccggagcg agcccagcgg gcccatctca acaatcaacc cctgtcctcc atgcaaggag 780
tgtcacaagt gccagctcc taacctcgag ggtggaccat ccgtcttcat cttccctcca 840
aatatcaagg atgtactcat gatctccctg acaccaagg tcacgtgtgt ggtgggtggat 900
gtgagcgagg atgaccaga cgtccagatc agctggtttg tgaacaacgt ggaagtacac 960
acagctcaga cacaaccga tagagaggat tacaacagta ctatccgggt ggtcagcacc 1020
20 ctccccatcc agcaccagga ctggatgagt ggcaaggagt tcaaagtcaa ggtcaacaac 1080
aaagacctcc catcaccatc cgagagaacc atctcaaaaa ttaaagggtc agtcagagct 1140
ccacaagtat acatcttgcc gccaccagca gagcagttgt ccaggaaaga tgtcagtcctc 1200
acttgctcgg tcgtgggctt caaccctgga gacatcagtg tggagtggac cagcaatggg 1260
catacagagg agaactacaa ggacaccgca ccagtcctgg actctgacgg ttcttacttc 1320
25 atatatagca agctcaatat gaaaacaagc aagtgggaga aaacagattc cttctcatgc 1380
aacgtgagac acgaggggtc gaaaaattac tacctgaaga agaccatctc ccggtctccg 1440
ggtaaatga 1449

<210> 8

30 <211> 482

<212> PRT

<213> Artificial Sequence

<220>

35 <223> synthetic

<400> 8

40

45

50

55

EP 2 509 409 B1

	Met	Asp	Trp	Thr	Trp	Arg	Ile	Leu	Phe	Leu	Val	Ala	Ala	Ala	Thr	Gly
	1				5					10					15	
	Ala	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
				20					25					30		
5	Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe
			35				40						45			
	Thr	Gly	Tyr	Tyr	Met	His	Trp	Phe	Arg	Gln	Ala	Pro	Gly	Gln	Glu	Cys
	50					55						60				
10	Glu	Leu	Met	Gly	Trp	Ile	Asn	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Tyr	Ala
	65				70						75					80
	Gln	Lys	Phe	Gln	Gly	Arg	Val	Thr	Met	Thr	Gly	Asp	Thr	Ser	Ile	Ser
				85						90					95	
	Thr	Ala	Tyr	Met	Glu	Leu	Ser	Arg	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val
				100					105					110		
15	Tyr	Tyr	Cys	Ala	Arg	Gly	Ser	Leu	Tyr	Cys	Thr	Asn	Gly	Val	Cys	Phe
			115				120						125			
	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Lys	Leu	Ser
	130						135						140			
	Lys	Thr	Thr	Pro	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Gly	Cys	Gly	Asp
	145					150					155					160
20	Thr	Thr	Gly	Ser	Ser	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys	Gly	Tyr	Phe
				165						170					175	
	Pro	Glu	Ser	Val	Thr	Val	Thr	Trp	Asn	Ser	Gly	Ser	Leu	Ser	Ser	Ser
				180					185					190		
25	Val	His	Thr	Phe	Pro	Ala	Leu	Leu	Gln	Ser	Gly	Leu	Tyr	Thr	Met	Ser
			195				200						205			
	Ser	Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Ser	Gln	Thr	Val	Thr
	210						215					220				

30

35

40

45

50

55

EP 2 509 409 B1

	Cys	Ser	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Thr	Val	Asp	Lys	Lys	Leu
	225					230					235					240
	Val	Arg	Ser	Glu	Pro	Ser	Gly	Pro	Ile	Ser	Thr	Ile	Asn	Pro	Cys	Pro
					245					250					255	
5	Pro	Cys	Lys	Glu	Cys	His	Lys	Cys	Pro	Ala	Pro	Asn	Leu	Glu	Gly	Gly
				260				265					270			
	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Asn	Ile	Lys	Asp	Val	Leu	Met	Ile
			275				280						285			
	Ser	Leu	Thr	Pro	Lys	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Glu	Asp
10		290					295					300				
	Asp	Pro	Asp	Val	Gln	Ile	Ser	Trp	Phe	Val	Asn	Asn	Val	Glu	Val	His
	305				310					315						320
	Thr	Ala	Gln	Thr	Gln	Thr	His	Arg	Glu	Asp	Tyr	Asn	Ser	Thr	Ile	Arg
				325					330						335	
15	Val	Val	Ser	Thr	Leu	Pro	Ile	Gln	His	Gln	Asp	Trp	Met	Ser	Gly	Lys
				340				345					350			
	Glu	Phe	Lys	Cys	Lys	Val	Asn	Asn	Lys	Asp	Leu	Pro	Ser	Pro	Ile	Glu
			355				360					365				
	Arg	Thr	Ile	Ser	Lys	Ile	Lys	Gly	Leu	Val	Arg	Ala	Pro	Gln	Val	Tyr
20		370					375					380				
	Ile	Leu	Pro	Pro	Pro	Ala	Glu	Gln	Leu	Ser	Arg	Lys	Asp	Val	Ser	Leu
	385				390					395						400
	Thr	Cys	Leu	Val	Val	Gly	Phe	Asn	Pro	Gly	Asp	Ile	Ser	Val	Glu	Trp
				405						410					415	
25	Thr	Ser	Asn	Gly	His	Thr	Glu	Glu	Asn	Tyr	Lys	Asp	Thr	Ala	Pro	Val
			420					425						430		
	Leu	Asp	Ser	Asp	Gly	Ser	Tyr	Phe	Ile	Tyr	Ser	Lys	Leu	Asn	Met	Lys
			435				440						445			
	Thr	Ser	Lys	Trp	Glu	Lys	Thr	Asp	Ser	Phe	Ser	Cys	Asn	Val	Arg	His
		450				455					460					
30	Glu	Gly	Leu	Lys	Asn	Tyr	Tyr	Leu	Lys	Lys	Thr	Ile	Ser	Arg	Ser	Pro
	465				470						475					480
	Gly	Lys														

<210> 9

35 <211> 1149

<212> DNA

<213> Artificial Sequence

<220>

40 <223> synthetic

<400> 9

45

50

55

EP 2 509 409 B1

	atggactgga	cctggaggat	cctttttcttg	gtggcagcag	ccacaggagc	ccactcccag	60
	gtgcagctgg	tgcagtctgg	ggctgagggtg	aagaagcctg	gggcctcagt	gaaggtctcc	120
	tgcaaggctt	ctggatacac	cttcaccggc	tactatatgc	actgggtgcg	acaggcccct	180
5	ggacaagggc	ttgagtggat	gggatggatc	aaccctaaca	gtggtggcac	aaactatgca	240
	cagaagtttc	agggcagggg	caccatgacc	ggggacacgt	ccatcagcac	agcctacatg	300
	gagctgagca	ggctgagatc	tgacgacacg	gcctgtgtatt	actgtgcgag	aggctcctta	360
	tattgtacta	atgggtgtatg	ccttgactac	tggggccagg	gaaccctggg	caccgtctcc	420
	tcatccggag	agcccagcgg	gcccatttca	acaatcaacc	cctgtcctcc	atgcaaggag	480
	tgtcacaaat	gcccagctcc	taacctcgag	ggtggaccat	ccgtcttcat	cttccctcca	540
10	aatatcaagg	atgtactcat	gatctccctg	acacccaagg	tcacgtgtgt	ggtggtggat	600
	gtgagcgagg	atgaccacga	cgtccagatc	agctggtttg	tgaacaacgt	ggaagtacac	660
	acagctcaga	cacaaaccca	tagagaggat	tacaacagta	ctatccgggt	ggtcagcacc	720
	ctccccatcc	agcaccagga	ctggatgagt	ggcaaggagt	tcaaatagca	ggtcaacaac	780
	aaagacctcc	catcacccat	cgagagaacc	atctcaaaaa	ttaaagggtc	agtcagagct	840
15	ccacaagtat	acatcttgcc	gccaccagca	gagcagttgt	ccaggaaaga	tgtcagtctc	900
	acttgccctg	tcgtgggctt	caaccctgga	gacatcagtg	tggagtggac	cagcaatggg	960
	catacagagg	agaactacaa	ggacaccgca	ccagtccttg	actctgacgg	ttcttacttc	1020
20	atatatagca	agctcaatat	gaaaacaagc	aagtgggaga	aaacagattc	cttctcatgc	1080
	aacgtgagac	acgaggggtc	gaaaaattac	tacctgaaga	agaccatctc	ccggtctccg	1140
	ggtaaatga						1149

<210> 10

<211> 382

25 <212> PRT

<213> Artificial Sequence

<220>

<223> synthetic

30

35

40

45

50

55

EP 2 509 409 B1

<400> 10
Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1 5 10 15
5 Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45
10 Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60
Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala
65 70 75 80
Gln Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Ile Ser
85 90 95
15 Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Ser Leu Tyr Cys Thr Asn Gly Val Cys Phe
115 120 125
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Gly Glu
130 135 140
20 Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu
145 150 155 160
Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val Phe
165 170 175
Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr Pro
180 185 190
25 Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val
195 200 205
Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr
210 215 220
30 Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser Thr
225 230 235 240
Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys
245 250 255
Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser
260 265 270
35 Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro
275 280 285
Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val
290 295 300
40 Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly
305 310 315 320
His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp Ser Asp
325 330 335
Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser Lys Trp
340 345 350
45 Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly Leu Lys
355 360 365
Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly Lys

50 370 375 380

<210> 11

<211> 1149

<212> DNA

55 <213> Artificial Sequence

<220>

<223> synthetic

<400> 11

```

5      atggactgga cctggaggat ccttttcttg gtggcagcag ccacaggagc ccactcccag 60
      gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt gaaggtctcc 120
      tgcaaggctt ctggatacac cttcaccggc tactatatgc actgggtttcg acaggcccct 180
      ggacaagagt gtgagttgat gggatggatc aaccctaaca gtggtggcac aaactatgca 240
      cagaagtttc agggcagggg caccatgacc ggggacacgt ccatcagcac agcctacatg 300
      gagctgagca ggctgagatc tgacgacacg gccgtgtatt actgtgcgag aggctcctta 360
10     tattgtacta atggtgtatg ctttgactac tggggccagg gaaccctggg caccgtctcc 420
      tcatccggag agcccagcgg gcccatattca acaatcaacc cctgtcctcc atgcaaggag 480
      tgtcacaagt gccccagctcc taacctcgag ggtggacat ccgtcttcat cttccctcca 540
      aatatcaagg atgtactcat gatctccctg acaccaagg tcacgtgtgt ggtgggtggat 600
      gtgagcgagg atgaccaga cgtccagatc agctggtttg tgaacaacgt ggaagtacac 660
      acagctcaga cacaaccaca tagagaggat tacaacagta ctatccgggt ggtcagcacc 720
15     ctccccatcc agcaccagga ctggatgagt ggcaaggagt tcaaagtaa ggtcaacaac 780
      aaagacctcc catcaccat cgagagaacc atctcaaaaa ttaaagggt agtcagagct 840
      ccacaagtat acatcttgcc gccaccagca gagcagttgt ccaggaaaga tgtcagcttc 900
      acttgccctg tctgtgggct caaccctgga gacatcagtg tggagtggac cagcaatggg 960
      catacagagg agaactacaa ggacaccgca ccagtcctgg actctgacgg ttcttacttc 1020
20     atatatagca agctcaatat gaaaaacaagc aagtgggaga aaacagattc cttctcatgc 1080
      aacgtgagac acgaggggtc gaaaaattac tacctgaaga agaccatctc ccggtctccg 1140
      ggtaaataga                                     1149

```

<210> 12

25 <211> 382

<212> PRT

<213> Artificial Sequence

<220>

30 <223> synthetic

<400> 12

```

35     Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
      1          5          10          15
      Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
      20          25          30
      Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
      35          40          45
40     Thr Gly Tyr Tyr Met His Trp Phe Arg Gln Ala Pro Gly Gln Glu Cys
      50          55          60
      Glu Leu Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala
      65          70          75          80
      Gln Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Ile Ser
45     85          90          95
      Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val
      100          105          110
      Tyr Tyr Cys Ala Arg Gly Ser Leu Tyr Cys Thr Asn Gly Val Cys Phe
      115          120          125
50     Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Glu
      130          135          140
      Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu

```

55

EP 2 509 409 B1

	145		150		155		160
	Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val Phe						
		165		170			175
5	Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr Pro						
		180		185			190
	Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val						
		195		200			205
	Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr						
		210		215			220
10	Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser Thr						
		225		230			235
	Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys						
		245		250			255
	Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser						
15		260		265			270
	Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro						
		275		280			285
	Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val						
		290		295			300
20	Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly						
		305		310			315
	His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp Ser Asp						
		325		330			335
	Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser Lys Trp						
		340		345			350
25	Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly Leu Lys						
		355		360			365
	Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly Lys						
		370		375			380

30 <210> 13
 <211> 19
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> synthetic

<400> 13
 caacacaagt gcgatgcac 19

40 <210> 14
 <211> 21
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> synthetic

50 <400> 14
 gattagcctc catgcctact c 21

<210> 15
 <211> 21
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> synthetic

<400> 15
 gatgatcatg tgggtagacc t 21

5 <210> 16
 <211> 20
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> synthetic

<400> 16
 tctatgctat ctcagtgccta 20

15 <210> 17
 <211> 49
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> synthetic

<400> 17
 tgacagtgtat atcacatata cttttcttg tagtcccaga agtatcatc 49

25 <210> 18
 <211> 384
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> synthetic

35 <400> 18

	gaggtccagc	ttcagcagtc	tggagctgag	ctggtgaggc	ctgggtcctc	agtgaagatg	60
	tcttgcaaga	cttctggata	tacattcaca	agctacggta	taaactgggt	gaagcagagg	120
	cctggacagg	gcctggaatg	gattggatat	atttatattg	gaaatgggta	tactgagtac	180
	aatgagaagt	tcaagggcaa	ggccacactg	acttcagaca	catcctccag	cacagcctac	240
40	atgcagctca	gcagcctgac	atctgaggac	tctgcaatct	atttcctgtc	aagaggacgg	300
	gtcggccccg	actactttga	ctactggggc	caaggcacca	ctctcacagt	ctcctcagtc	360
	ccagaagtat	catctgtctt	catc				384

45 <210> 19
 <211> 128
 <212> PRT
 <213> Artificial Sequence

50 <220>
 <223> synthetic

<400> 19

55

EP 2 509 409 B1

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 5 Gly Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Tyr Ile Gly Asn Gly Tyr Thr Glu Tyr Asn Glu Lys Phe
 50 55 60
 10 Lys Gly Lys Ala Thr Leu Thr Ser Asp Thr Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Phe Arg
 85 90 95
 15 Ala Arg Gly Arg Val Gly Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Thr Leu Thr Val Ser Ser Val Pro Glu Val Ser Ser Val Phe Ile
 115 120 125

<210> 20
 <211> 381
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic

<400> 20

gaggtccagc tgcaacagtc tggacgtgag ctgggtcaagc ctgggggcttc agtgatgata 60
 30 tcttgtaacg cttctggata cacgttcatt gactacttca taaactggat gaagcggagc 120
 catggacaga gccttgagtg gattggagat attaataccta acaatgggtg ttctaactac 180
 aaccagaagt tcaagggcaa ggccacattg actgtagaca agtcctccag cacagcctac 240
 atggatctcc gcagcctgac atctgaagac tctgcagtct attactgtgc aaaactggga 300
 cgggactggg acttcgatgt ctgggggcaca gggaccacgg tcaccgtctc ctcagtccca 360
 35 gaagtatcat ctgtcttcat c 381

<210> 21
 <211> 127
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> synthetic

<400> 21

50

55

EP 2 509 409 B1

	Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Arg	Glu	Leu	Val	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Met	Ile	Ser	Cys	Thr	Ala	Ser	Gly	Tyr	Thr	Phe	Ile	Asp	Tyr
				20					25					30		
5	Phe	Ile	Asn	Trp	Met	Lys	Arg	Ser	His	Gly	Gln	Ser	Leu	Glu	Trp	Ile
			35					40					45			
	Gly	Asp	Ile	Asn	Pro	Asn	Asn	Gly	Gly	Ser	Asn	Tyr	Asn	Gln	Lys	Phe
		50					55					60				
	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
10		65				70					75					80
	Met	Asp	Leu	Arg	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
	Ala	Lys	Leu	Gly	Arg	Asp	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Thr	Gly	Thr
			100						105					110		
15	Thr	Val	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile	
			115					120					125			

<210> 22

<211> 375

20 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

25

<400> 22

	caggtccaac	tgcagcagcc	tggggctgag	cttgtgaagc	ctggggcttc	agtgaagctg	60
	tcctgcaagg	cttctggcta	caccttcacc	agctactgga	tgcagtgggt	aaaacagagg	120
30	cctggacagg	gccttgagtg	gatcggagag	attgatcctt	ctgatagcta	tactaactac	180
	aatcaaaagt	tcaagggcaa	ggccacattg	actgtagaca	catcctccag	cacagcctac	240
	atgcagctca	gcagcctgac	acctgaggac	tctgoggtct	attactgtgc	aagatgtagg	300
	tactactttg	actactgggg	ccaaggcacc	actctcacag	tctcctcagt	cccagaagta	360
	tcattctgtct	tcata					375

35

<210> 23

<211> 125

<212> PRT

<213> Artificial Sequence

40

<220>

<223> synthetic

<400> 23

45

50

55

EP 2 509 409 B1

	Gln	Val	Gln	Leu	Gln	Gln	Pro	Gly	Ala	Glu	Leu	Val	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Leu	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
				20					25					30		
5	Trp	Met	Gln	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
			35					40					45			
	Gly	Glu	Ile	Asp	Pro	Ser	Asp	Ser	Tyr	Thr	Asn	Tyr	Asn	Gln	Lys	Phe
		50					55					60				
	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Thr	Ser	Ser	Ser	Thr	Ala	Tyr
10	65					70					75					80
	Met	Gln	Leu	Ser	Ser	Leu	Thr	Pro	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
	Ala	Arg	Cys	Arg	Tyr	Tyr	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Leu
				100					105					110		
15	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile			
			115					120					125			

<210> 24

<211> 393

20 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

25

<400> 24

	gaggttcagt	tgcagcagtc	tggggcagag	attgtgaagt	caggggcctc	agtcaagttg	60
	tcctgcacag	cttctggctt	caacatgaaa	gactacttta	tccactgggt	gaagcagagg	120
30	actgaacagg	gcctggagtg	gattggaagg	cttgatcctg	aggatggtaa	aactaaatat	180
	gccccgaaat	tccagggcaa	ggccactata	acagcagaca	catcctccaa	cacagcctac	240
	ctgcacctca	gcagcctgac	atctgaggac	actgccgtct	attactgtgc	tagaggggga	300
	ctgggacgtg	aggaatacta	tgtgtgtggac	tactgggggtc	aaggaacctc	agtcaccgtc	360
	tcctcagtc	cagaagtata	atctgtcttc	atc			393

35

<210> 25

<211> 131

<212> PRT

<213> Artificial Sequence

40

<220>

<223> synthetic

<400> 25

45

50

55

EP 2 509 409 B1

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Ile Val Lys Ser Gly Ala
 1 5 10 15
 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Met Lys Asp Tyr
 20 25 30
 Phe Ile His Trp Val Lys Gln Arg Thr Glu Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Arg Leu Asp Pro Glu Asp Gly Lys Thr Lys Tyr Ala Pro Lys Phe
 50 55 60
 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
 65 70 75 80
 Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Gly Leu Gly Arg Glu Glu Tyr Tyr Ala Val Asp Tyr Trp
 100 105 110
 Gly Gln Gly Thr Ser Val Thr Val Ser Ser Val Pro Glu Val Ser Ser
 115 120 125
 Val Phe Ile
 130

20 <210> 26
 <211> 387
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> synthetic

<400> 26

30 gatgtacagc ttcaggagtc aggacctggc ctcgtgaaac cttctcagtc tctgtctctc 60
 acctgctctg tcaactggcta ctccatcacc agtgggttatt actggaactg gatccggcag 120
 tttccaggaa acaaaactgga atggatgggc tacataagct acgatggtag gaataactac 180
 aacccatctc tcaaaaatcg aatctccatc actcgtgaca catctaagaa ccagtttttc 240
 ctgaagttga attctgtgac tactgaggac acagccacat attactgtgc aatccatacg 300
 35 gtagtagggg actatgttat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360
 gtcccagaag tatcatctgt cttcatc 387

40 <210> 27
 <211> 129
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> synthetic

<400> 27

50

55

EP 2 509 409 B1

	Asp	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Ser	Gln
	1				5					10					15	
	Ser	Leu	Ser	Leu	Thr	Cys	Ser	Val	Thr	Gly	Tyr	Ser	Ile	Thr	Ser	Gly
				20					25					30		
5	Tyr	Tyr	Trp	Asn	Trp	Ile	Arg	Gln	Phe	Pro	Gly	Asn	Lys	Leu	Glu	Trp
			35					40					45			
	Met	Gly	Tyr	Ile	Ser	Tyr	Asp	Gly	Arg	Asn	Asn	Tyr	Asn	Pro	Ser	Leu
		50					55					60				
	Lys	Asn	Arg	Ile	Ser	Ile	Thr	Arg	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Phe
10		65				70					75					80
	Leu	Lys	Leu	Asn	Ser	Val	Thr	Thr	Glu	Asp	Thr	Ala	Thr	Tyr	Tyr	Cys
				85					90					95		
	Ala	Ile	His	Thr	Val	Val	Gly	Asp	Tyr	Val	Met	Asp	Tyr	Trp	Gly	Gln
				100				105					110			
15	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser	Ser	Val	Phe

		115		120		125
	Ile					

20 <210> 28
 <211> 378
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> synthetic

<400> 28

30	gagggttcagc	tgcagcagtc	tggggcagag	cttgtgaggc	caggggcctc	agtcaagttg	60
	tcctgcacag	cttctggctt	caacattaaa	gactactata	tacactgggt	gaagaagagg	120
	cctgaacagg	gcctggagtg	gattggaagg	attgatcctg	aggatggtga	tactgagtat	180
	gccccgaagt	tccagggcaa	ggccactatg	actgcagaca	catcctccaa	cacagcctac	240
	cttcagctca	gcagcctgac	atctgaggac	attgocgtot	attactgtac	tacatctagg	300
35	cctttttatt	ttgactactg	gggccaaggc	accactctca	cagtctcctc	agtcccagaa	360
	gtatcatctg	tcttcatc					378

<210> 29
 <211> 126
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> synthetic

<400> 29

50

55

EP 2 509 409 B1

	Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Asn	Ile	Lys	Asp	Tyr
5				20					25					30		
	Tyr	Ile	His	Trp	Val	Lys	Lys	Arg	Pro	Glu	Gln	Gly	Leu	Glu	Trp	Ile
			35					40					45			
	Gly	Arg	Ile	Asp	Pro	Glu	Asp	Gly	Asp	Thr	Glu	Tyr	Ala	Pro	Lys	Phe
		50					55					60				
10	Gln	Gly	Lys	Ala	Thr	Met	Thr	Ala	Asp	Thr	Ser	Ser	Asn	Thr	Ala	Tyr
	65					70					75				80	
	Leu	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ile	Ala	Val	Tyr	Tyr	Cys
					85					90				95		
	Thr	Thr	Ser	Arg	Pro	Phe	Tyr	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Thr
				100					105					110		
15	Leu	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile		
			115					120					125			

<210> 30

20 <211> 369

<212> DNA

<213> Artificial Sequence

<220>

25 <223> synthetic

<400> 30

30 gaggttcagc tgcagcagtc tgggacagaa cttgtgaagc caggggcctc agccaagttg 60
tcctgcacag cttctggctt caacgttaaa gactacttta tgcactgggt gaagcagaag 120
actgaacagg gcctggagtg gattggaagg attgttcctg aggatgggga aactaagtct 180

35 gccccgaaat tccaggacag gaccactata agaacagaca catcctocaa cacatctcac 240
ctacaactca acagcctgac atctgaggac actgccgtct attactgtgc tagacctaac 300
cccccttact ggggccaagg gactctggtc actgtctctg tagtcccaga agtatcatct 360
gtcttcac 369

40 <210> 31

<211> 123

<212> PRT

<213> Artificial Sequence

45 <220>

<223> synthetic

<400> 31

50

55

EP 2 509 409 B1

Glu Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Ala Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Val Lys Asp Tyr
 20 25 30
 Phe Met His Trp Val Lys Gln Lys Thr Glu Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Arg Ile Val Pro Glu Asp Gly Glu Thr Lys Ser Ala Pro Lys Phe
 50 55 60
 Gln Asp Arg Thr Thr Ile Arg Thr Asp Thr Ser Ser Asn Thr Ser His
 65 70 75 80
 Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Pro Asn Pro Pro Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
 100 105 110
 Ser Val Val Pro Glu Val Ser Ser Val Phe Ile
 115 120

<210> 32

<211> 399

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

<400> 32

gaggtgaaac tgggtggaatc tggaggaggc ttggttcagt ctgggcgttc tctgagactc 60
 tcctgtgcaa cttctgggtt caccttcagt gatttctaca tggagtgggt ccgccaagct 120
 ccagggaagg gactggagtg gattgctaca agtagaaaca aacttaatga ttatacacca 180
 gaattcagtg catctgtgaa gggtcgattc atcgtctcca gagacacttc ccaaaacatc 240
 ctctaccttc agatgaatgc cctgagacct gaggacactg ccatttatta ctgtgcaaga 300
 gcctgtagtg actacgaccg ttactatgct atggactatt ggggtcaagg aacctcagtc 360
 accgtctcct cagtcgccaga agtatcatct gtcttcate 399

<210> 33

<211> 133

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic

<400> 33

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Phe

EP 2 509 409 B1

5 Tyr Met Glu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 10 Ala Thr Ser Arg Asn Lys Leu Asn Asp Tyr Thr Pro Glu Phe Ser Ala
 50 55 60
 Ser Val Lys Gly Arg Phe Ile Val Ser Arg Asp Thr Ser Gln Asn Ile
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ala Leu Arg Pro Glu Asp Thr Ala Ile Tyr
 85 90 95
 15 Tyr Cys Ala Arg Ala Cys Ser Asp Tyr Asp Arg Tyr Tyr Ala Met Asp
 100 105 110
 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Val Pro Glu Val
 115 120 125
 Ser Ser Val Phe Ile
 130

<210> 34

<211> 399

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

<400> 34

caggtccaac tgcagcagcc tggggctgag cttgtgaagc ctggggcttc agtgaagctg 60
 tcctgcaagg cttctggcta caccttcacc agctactgga tgcactgggt gaagcagagg 120
 cctggacgag gccttgagtg gattggaagg attgatccta atagtgggtg tactaagtac 180
 aatgagaagc tcaagaacaa ggccacactg actgtagaca aaccctccag cacagcctac 240
 atgcagctca gcagcctgac atctgaggac tctgcggtct attattgtgc aagagaggag 300
 ataaattact acggtagtag ctacggtgct atggactact ggggtcaagg aacctcagtc 360
 accgtctcct cagtcccaga agtatcatct gtcttcac 399

<210> 35

<211> 133

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic

<400> 35

EP 2 509 409 B1

	Gln	Val	Gln	Leu	Gln	Gln	Pro	Gly	Ala	Glu	Leu	Val	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Leu	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
				20				25						30		
5	Trp	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Gly	Arg	Gly	Leu	Glu	Trp	Ile
			35				40						45			
	Gly	Arg	Ile	Asp	Pro	Asn	Ser	Gly	Gly	Thr	Lys	Tyr	Asn	Glu	Lys	Leu
	50					55						60				
	Lys	Asn	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Pro	Ser	Ser	Thr	Ala	Tyr
10	65					70					75				80	
	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85						90					95	
	Ala	Arg	Glu	Glu	Ile	Asn	Tyr	Tyr	Gly	Ser	Thr	Tyr	Gly	Ala	Met	Asp
			100						105					110		
15	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Val	Pro	Glu	Val
			115					120					125			
	Ser	Ser	Val	Phe	Ile											
			130													

20 <210> 36
 <211> 375
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> synthetic

<400> 36

30	gaggtccagc	tgcagcagtc	tggaacctgag	ctggtgaagc	ctggggccttc	agtgaagata	60
	tcctgcaagg	cttctgggta	ctcattcact	ggctactaca	tgaactgggt	gaagcaaagt	120
	cctgaaaaga	gccttgagtg	gattggagag	attaatccta	gcactgggtg	tactacctac	180
	aaccagaagt	tcaaggccaa	ggccacattg	actgtagaca	aatcctccag	cacagcctac	240
	atgcagctca	agagcctgac	atctgaggac	tctgcagtct	attactgtgc	aggtgggttac	300
35	tggtacttcg	atgtctgggg	cacagggacc	acggtcaccg	tctcctcagt	cccagaagta	360
	tcattctgtct	tcattc					375

40 <210> 37
 <211> 125
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> synthetic

<400> 37

50

55

EP 2 509 409 B1

	Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe	Thr	Gly	Tyr
			20					25					30			
5	Tyr	Met	Asn	Trp	Val	Lys	Gln	Ser	Pro	Glu	Lys	Ser	Leu	Glu	Trp	Ile
			35				40						45			
	Gly	Glu	Ile	Asn	Pro	Ser	Thr	Gly	Gly	Thr	Thr	Tyr	Asn	Gln	Lys	Phe
		50				55						60				
	Lys	Ala	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
10	65					70					75					80
	Met	Gln	Leu	Lys	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85						90					95	
	Ala	Gly	Gly	Tyr	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Thr	Gly	Thr	Thr	Val
			100					105					110			
15	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile			
			115					120					125			

<210> 38

<211> 396

20 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

25

<400> 38

	gaggtgcagc	tggtggagtc	tgggggagac	ttagtggagc	ctggaggggc	cctgaaactc	60
30	tcctgtgcag	cctctggatt	cactttcagt	agctatggca	tgtcttgggt	tcgccagact	120
	ccagacaaga	ggctggagtg	ggtcgcaacc	attagtagtg	gtggtagtta	cacctactat	180
	ccagacagtg	tgaaggggcg	attcaccatc	tccagagaca	atgccaaagaa	caccctgtac	240
	ctgcaaataa	gcagtctgaa	gtctgaggac	acagccatgt	attactgtgc	aagacatgat	300
	tactacggta	gtagctacgg	gtggtacttc	gatgtctggg	gcacagggac	cacggtcacc	360

35

gtctcctcag	tcccagaagt	atcatctgtc	ttcacc	396
------------	------------	------------	--------	-----

<210> 39

40 <211> 132

<212> PRT

<213> Artificial Sequence

<220>

45 <223> synthetic

<400> 39

50

55

EP 2 509 409 B1

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Asp	Leu	Val	Glu	Pro	Gly	Gly
	1				5					10					15	
	Ser	Leu	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
5	Gly	Met	Ser	Trp	Val	Arg	Gln	Thr	Pro	Asp	Lys	Arg	Leu	Glu	Trp	Val
			35					40					45			
	Ala	Thr	Ile	Ser	Ser	Gly	Gly	Ser	Tyr	Thr	Tyr	Tyr	Pro	Asp	Ser	Val
		50					55					60				
	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
10	65					70				75					80	
	Leu	Gln	Met	Ser	Ser	Leu	Lys	Ser	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
				85					90					95		
	Ala	Arg	His	Asp	Tyr	Tyr	Gly	Ser	Ser	Tyr	Gly	Trp	Tyr	Phe	Asp	Val
				100				105						110		
15	Trp	Gly	Thr	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Val	Pro	Glu	Val	Ser
			115					120					125			
	Ser	Val	Phe	Ile												
				130												

20 <210> 40
 <211> 24
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> synthetic

<400> 40
 cgatgggggc agggaaagct gcac 24

30 <210> 41
 <211> 16
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> synthetic

40 <400> 41
 gtaaaacgac ggccag 16

<210> 42
 <211> 17
 <212> DNA
 45 <213> Artificial Sequence

<220>
 <223> synthetic

50 <400> 42
 caggaaacag ctatgac 17

<210> 43
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence

<220>

<221> variation
 <222> (14)...(14)
 <223> s = c or g

5 <220>
 <223> synthetic

 <400> 43
 10 tcaccatgga ctgsacctgg a 21

 <210> 44
 <211> 22
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <221> variation
 <222> (17)...(17)
 <223> y = c or t

20 <220>
 <223> synthetic

 <400> 44
 25 ccatggacac acttgytcc ac 22

 <210> 45
 <211> 23
 <212> DNA
 30 <213> Artificial Sequence

 <220>
 <223> synthetic

35 <400> 45
 tcaccatgga gttgggctg agc 23

 <210> 46
 <211> 25
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <221> variation
 45 <222> (14)...(14)
 <223> y = c or t

 <220>
 <223> synthetic

50 <400> 46
 agaacatgaa acayctgtgg ttctt 25

 <210> 47
 55 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic

5 <400> 47
 atggggtcaa ccgccatcct 20

<210> 48
 <211> 23
 <212> DNA
 10 <213> Artificial Sequence

<220>
 <223> synthetic

15 <400> 48
 acaatgtctg tctccttct cat 23

<210> 49
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic

25 <400> 49
 gcaaggctta caaccacaat c 21

<210> 50
 <211> 381
 <212> DNA
 30 <213> Artificial Sequence

<220>
 <223> synthetic

35 <400> 50

40 caggtgcagc tgggtgcagtc tgggggtgag gtgaagaagc ctgggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120
 actggacaag ggcttgagtg gatgggatgg atgaacccta atagtggtaa gacaggctat 180
 gcacagaagt tccagggcag agtcgccatg accaggaaaa cctccataag cacagcctac 240
 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagaggac 300
 tacagtaact acggggactt tgactactgg ggccaggga ccttggtcac cgtctcctca 360
 45 gtgccaggg attgtggttg t 381

<210> 51
 <211> 127
 <212> PRT
 50 <213> Artificial Sequence

<220>
 <223> synthetic

55 <400> 51

EP 2 509 409 B1

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
				20				25						30		
5	Asp	Ile	Asn	Trp	Val	Arg	Gln	Ala	Thr	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35				40						45			
	Gly	Trp	Met	Asn	Pro	Asn	Ser	Gly	Lys	Thr	Gly	Tyr	Ala	Gln	Lys	Phe
		50				55						60				
	Gln	Gly	Arg	Val	Ala	Met	Thr	Arg	Lys	Thr	Ser	Ile	Ser	Thr	Ala	Tyr
10	65					70					75					80
	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95		
	Ala	Arg	Glu	Asp	Tyr	Ser	Asn	Tyr	Gly	Asp	Phe	Asp	Tyr	Trp	Gly	Gln
				100				105						110		
15	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Val	Pro	Arg	Asp	Cys	Gly	Cys	
			115					120					125			

<210> 52

<211> 378

20 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

25 <400> 52

	cagggttcagc	tggtgcagtc	tgagagctgag	atgaagaagc	ctgggggcctc	agtgaagggtc	60
	tcctgcaagg	cttctgggta	cacctttacc	agctatggta	tcagctgggt	gcgacaggcc	120
30	cctggacaag	ggcttgagtg	gatgggatgg	atcagcgctt	acaatggtaa	cacatactat	180
	gcacagaacc	tccagggcag	agtcaccatg	accacagaca	catccaagag	cgcagccttc	240
	atggacctga	ggagcctgag	atctgacgac	acggccgtgt	attactgtgc	gagagatggg	300
	tatagtacct	cgtccttaga	ctactggggc	caggggaacc	tggtcacctg	ctcctcagtg	360
	cccagggatt	gtggttgt					378

35 <210> 53

<211> 126

<212> PRT

<213> Artificial Sequence

40 <220>

<223> synthetic

45 <400> 53

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Met	Lys	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
				20				25						30		
50	Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35				40						45			
	Gly	Trp	Ile	Ser	Ala	Tyr	Asn	Gly	Asn	Thr	Tyr	Tyr	Ala	Gln	Asn	Leu
		50					55					60				

55

EP 2 509 409 B1

Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Ala Ala Phe
 65 70 75 80
 Met Asp Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 5 Ala Arg Asp Gly Tyr Ser Thr Ser Ser Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Leu Val Thr Val Ser Ser Val Pro Arg Asp Cys Gly Cys
 115 120 125
 10 <210> 54
 <211> 378
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> synthetic
 <400> 54
 20 caggttcagc tgggtgcagtc tggagctgag atgaagaagc ctgggggcctc agtgaagggtc 60
 tcttgcaagg cttctgggta cacctttacc agctatggta tcagctgggt gcgacaggcc 120
 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacatactat 180
 gcacagaacc tccagggcag agtcaccatg accacagaca catccacgag cgcagccttc 240
 atggacctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagatggg 300
 25 tatagtacct cgtccttaga ctactggggc caggggaaccc tgggtcacctg ctctcagtg 360
 cccagggatt gtggttgt 378
 <210> 55
 <211> 126
 30 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> synthetic
 35 <400> 55
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Met Lys Lys Pro Gly Ala
 1 5 10 15
 40 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Tyr Tyr Ala Gln Asn Leu
 50 55 60
 45 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Ala Ala Phe
 65 70 75 80
 Met Asp Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 50 Ala Arg Asp Gly Tyr Ser Thr Ser Ser Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Leu Val Thr Val Ser Ser Val Pro Arg Asp Cys Gly Cys
 115 120 125
 <210> 56
 55 <211> 408
 <212> DNA
 <213> Artificial Sequence

EP 2 509 409 B1

<220>

<223> synthetic

<400> 56

```

5      caggttcagc tgggtgcagtc tggagctgag gtgaagaagc ctgggggcctc agtgaagggtc 60
      tcctgcaagg cttctgggta cacctttacc agctatggta tcagctgggt ggcacaggcc 120
      cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180
      gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
10     atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagatgat 300
      atgattacgt ttgggggagt tatcgccaac tactactact acgggtatgga cgtctggggc 360
      caagggacca cggtcaccgt cacctcagtg cccagggatt gtggttgt 408

```

<210> 57

15 <211> 136

<212> PRT

<213> Artificial Sequence

<220>

20 <223> synthetic

<400> 57

```

25     Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
      1          5          10          15
      Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20
      Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35          40          45
30     Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
      50          55          60
      Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
      65          70          75          80
      Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
      85          90          95
35     Ala Arg Asp Asp Met Ile Thr Phe Gly Gly Val Ile Ala Asn Tyr Tyr
      100          105          110
      Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Thr
      115          120          125
40     Ser Val Pro Arg Asp Cys Gly Cys
      130          135

```

<210> 58

<211> 372

45 <212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

50

<400> 58

55

EP 2 509 409 B1

5 caggttcagt tgctgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaagggtc 60
 tcctacaagg cttctgatta cacctttacc agctatggta tcagctgggt gcgacaggcc 120
 cctggacaag ggcttgagt gatgggatgg atcagcgctt acaatggtaa cacaaactat 180
 gcacagaacc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
 atggaactga ggagcctgag atctgacgac tcggccgtgt attactgtgc gagagaggag 300
 ctggaacttt ttgactactg gggccaggga accctgggtca cegtctcctc agtgcccagg 360
 gattgtggtt gt 372

<210> 59

10 <211> 124

<212> PRT

<213> Artificial Sequence

<220>

15 <223> synthetic

<400> 59

20 Gln Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Tyr Lys Ala Ser Asp Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 25 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Asn Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 30 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Glu Glu Leu Glu Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser Val Pro Arg Asp Cys Gly Cys
 115 120

35 <210> 60

<211> 378

<212> DNA

<213> Artificial Sequence

40 <220>

<223> synthetic

<400> 60

45 caggtccagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaagggtc 60
 tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120
 cctggacaag ggcttgagt gatgggaggg atcatcccta tctttggtac agcaaactac 180
 gcacagaagt tccagggcag agtcacgatt accacggacg aatccacgag cacagcctac 240
 50 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatggg 300
 tatagtacct cgtccttaga ctactggggc caggggaaccc tggtcaccgt ctctcagtg 360
 cccaggggatt gtggttgt 378

55 <210> 61

<211> 126

<212> PRT

<213> Artificial Sequence

EP 2 509 409 B1

<220>

<223> synthetic

<400> 61

5

10

15

20

25

30

35

40

45

50

55

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
          20           25           30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

          35           40           45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Ser Thr Ala Tyr
65          70          75          80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95
Ala Arg Asp Gly Tyr Ser Thr Ser Ser Leu Asp Tyr Trp Gly Gln Gly
100         105         110
Thr Leu Val Thr Val Ser Ser Val Pro Arg Asp Cys Gly Cys
          115         120         125

```

<210> 62

<211> 390

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic

<400> 62

```

cagggtccagc tgggtgcagtc tgggggctgag gtgaagaagc ctggggtcctc ggtgaagggtc 60
tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaggg atcatcccta tcttttggtac agcaaactac 180
gcacagaagt tccagggcag agtcacgatt accacggacg aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc ggttatagca 300
gtggctggtg cctactacta ctacggtatg gacgtctggg gccaaaggac cacggtcacc 360
gtctccttag tgcccaggga ttgtggttgt                                     390

```

<210> 63

<211> 130

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic

<400> 63

5 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
 20 25 30
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
 50 55 60
 15 Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Val Ile Ala Val Ala Gly Thr Tyr Tyr Tyr Tyr Gly Met Asp Val
 100 105 110
 20 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Leu Val Pro Arg Asp Cys
 115 120 125
 Gly Cys
 130
 25 <210> 64
 <211> 101
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> synthetic
 <400> 64
 35 tgacagtgtgta atcacatata ctttttcttg tagtgcccag ggattgtggt tgtaagcctt 60
 gcatatgtac aggtaagtca gtaggccttt caccctgacc c 101

Claims

1. A transgenic mouse comprising a germline modification, which modification comprises:

(a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene;
and

(b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a); wherein the mouse comprises an intact IgM constant region gene, wherein the mouse expresses an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the mouse secretes said IgG heavy chain antibody into its serum.

2. The mouse of claim 1, wherein the IgG constant region gene is selected from the group consisting of an IgG1 constant region gene, an IgG2b constant region gene, a IgG2a constant region gene, and combinations thereof.

3. The mouse of claim 2, wherein the IgG constant region gene is an IgG1 constant region gene.

4. The mouse of claim 3, **characterised in that** the mouse additionally expresses:

(a) wild-type IgG3 protein;
(b) wild-type IgG2a protein; and
(c) wild-type IgG2b protein.

5. The mouse of claim 4, further **characterised in that** the mouse expresses:

- (a) wild-type IgM protein;
- (b) wild-type IgD protein;
- (c) wild-type IgA protein; and
- (d) wild-type IgE protein.

6. The mouse of claim 1, **characterised in that** the IgG heavy chain antibody lacks the CH1 domain: (a) in whole; or (b) in part.

7. The mouse of claim 1, wherein the IgG heavy chain antibody comprises the human variable domain, an IgG1 hinge, a CH2 domain, and a CH3 domain.

8. The mouse of claim 1, wherein the mouse comprises a functional immunoglobulin light chain gene locus.

9. The mouse of claim 8, wherein the immunoglobulin light chain gene locus is a κ light chain gene locus.

10. The mouse of claim 8, wherein the immunoglobulin light chain gene locus is a λ light chain gene locus.

11. The mouse of claim 1, wherein the mouse is from a strain selected from the group consisting of a 129 strain, a C57BL/6 strain, and a mixed 129xC57BL/6 strain.

12. The mouse of claim 11, wherein the mouse is 50% 129 and 50% C57BL/6.

13. An isolated mouse cell wherein the cell comprises a modification comprising:

- (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and
- (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a);

wherein the cell comprises an intact IgM constant region gene, wherein the cell expresses an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the cell secretes said IgG heavy chain antibody.

14. A mouse embryonic stem (ES) cell that comprises a modification comprising:

- (a) a deletion of a nucleic acid sequence encoding a CH1 domain of an endogenous IgG constant region gene; and
- (b) an inclusion of one or more human heavy chain variable region gene segments, wherein the one or more human heavy chain variable region gene segments is operably linked to the endogenous IgG constant region of (a);

wherein the ES cell comprises an intact IgM constant region gene, wherein the ES cell can give rise to a mouse expressing an IgG heavy chain antibody comprising a human variable domain, lacking a functional CH1 domain and lacking a cognate light chain, and wherein the mouse secretes said IgG heavy chain antibody into its serum.

Patentansprüche

1. Transgene Maus, umfassend eine Keimbahnmodifikation, wobei die Modifikation Folgendes umfasst:

- (a) eine Deletion einer Nucleinsäuresequenz, codierend eine CH1-Domäne eines endogenen IgG-Konstante-Region-Gens und
- (b) eine Aufnahme von ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmenten, wobei die ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmente operativ mit der endogenen IgG-Konstante-Region von (a) verknüpft ist/sind,

wobei die Maus ein intaktes IgM-Konstante-Region-Gen umfasst, wobei die Maus einen IgG-Schwere-Kette-Anti-

körper exprimiert, der eine humane variable Domäne umfasst, dem eine funktionelle CH1-Domäne fehlt, und dem eine verwandte leichte Kette fehlt, und wobei die Maus den IgG-Schwere-Kette-Antikörper in ihr Serum sezerniert.

2. Maus gemäß Anspruch 1, wobei das IgG-Konstante-Region-Gen ausgewählt ist aus der Gruppe, bestehend aus einem IgG1-Konstante-Region-Gen, einem IgG2b-Konstante-Region-Gen, einem IgG2a-Konstante-Region-Gen, und Kombinationen davon.

3. Maus gemäß Anspruch 2, wobei das IgG-Konstante-Region-Gen ein IgG1-Konstante-Region-Gen ist.

4. Maus gemäß Anspruch 3, **dadurch gekennzeichnet, dass** die Maus zusätzlich Folgendes exprimiert:

- (a) Wildtyp-IgG3-Protein
- (b) Wildtyp-IgG2a-Protein, und
- (c) Wildtyp-IgG2b-Protein.

5. Maus gemäß Anspruch 4, ferner **dadurch gekennzeichnet, dass** die Maus Folgendes exprimiert:

- (a) Wildtyp-IgM-Protein,
- (b) Wildtyp-IgD-Protein,
- (c) Wildtyp-IgA-Protein, und
- (d) Wildtyp-IgE-Protein.

6. Maus gemäß Anspruch 1, **dadurch gekennzeichnet, dass** dem IgG-Schwere-Kette-Antikörper die CH1-Domäne (a) vollständig, oder (b) teilweise fehlt.

7. Maus gemäß Anspruch 1, wobei der IgG-Schwere-Kette-Antikörper die humane variable Domäne, ein IgG1-Gelenk, eine CH2-Domäne und eine CH3-Domäne umfasst.

8. Maus gemäß Anspruch 1, wobei die Maus einen funktionellen Immunglobulin-Leichte-Kette-Gen-Lokus umfasst.

9. Maus gemäß Anspruch 8, wobei der Immunglobulin-Leichte-Kette-Gen-Lokus ein κ -Leichte-Kette-Gen-Lokus ist.

10. Maus gemäß Anspruch 8, wobei der Immunglobulin-Leichte-Kette-Gen-Lokus ein λ -Leichte-Kette-Gen-Lokus ist.

11. Maus gemäß Anspruch 1, wobei die Maus von einem Stamm ist, der aus der Gruppe, bestehend aus einem 129-Stamm, einem C57BL/6-Stamm und einem gemischten 129xC57BL/6-Stamm ausgewählt ist.

12. Maus gemäß Anspruch 11, wobei die Maus 50% 129 und 50% C57BL/6 ist.

13. Isolierte Mauszelle, wobei die Zelle eine Modifikation umfasst, welche Folgendes umfasst:

- (a) eine Deletion einer Nucleinsäuresequenz, codierend eine CH1-Domäne eines endogenen IgG-Konstante-Region-Gens und
- (b) eine Aufnahme von ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmenten, wobei die ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmente operativ mit der endogenen IgG-Konstante-Region von (a) verknüpft ist/sind,

wobei die Zelle ein intaktes IgM-Konstante-Region-Gen umfasst, wobei die Zelle einen IgG-Schwere-Kette-Antikörper exprimiert, der eine humane variable Domäne umfasst, dem eine funktionelle CH1-Domäne fehlt, und dem eine verwandte leichte Kette fehlt, und wobei die Zelle den IgG-Schwere-Kette-Antikörper sezerniert.

14. Embryonale Mausstamm-(ES)-Zelle, welche eine Modifikation umfasst, welche Folgendes umfasst:

- (a) eine Deletion einer Nucleinsäuresequenz, codierend eine CH1-Domäne eines endogenen IgG-Konstante-Region-Gens und
- (b) eine Aufnahme von ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmenten, wobei die ein oder mehreren humanen Schwere-Kette-Variable-Region-Gensegmente operativ mit der endogenen IgG-Konstante-Region von (a) verknüpft ist/sind,

wobei die ES-Zelle ein intaktes IgM-Konstante-Region-Gen umfasst, wobei sich die ES-Zelle zu einer Maus entwickeln kann, die einen IgG-Schwere-Kette-Antikörper exprimiert, der eine humane variable Domäne umfasst, dem eine funktionelle CH1-Domäne fehlt, und dem eine verwandte leichte Kette fehlt, und wobei die Maus den IgG-Schwere-Kette-Antikörper in ihr Serum sezerniert.

Revendications

1. Souris transgénique comportant une modification de lignée germinale, laquelle modification comprend :

- a) la délétion d'une séquence d'acide nucléique, codant un domaine CH1, d'un gène de région constante d'IgG endogène ;
- b) et l'inclusion d'un ou de plusieurs segment(s) de gène humain de région variable de chaîne lourde, lequel ou lesquels segment(s) de gène humain de région variable de chaîne lourde est ou sont opérationnellement raccordé(s) au reste du gène de région constante d'IgG endogène de l'item (a) ;

étant entendu que la souris comporte un gène intact de région constante d'IgM, que la souris exprime un anticorps chaîne lourde d'IgG qui comporte un domaine variable humain, n'a pas de domaine CH1 fonctionnel et n'est pas accompagné d'une chaîne légère, et que la souris sécrète ledit anticorps chaîne lourde d'IgG dans son sérum.

2. Souris conforme à la revendication 1, dans laquelle le gène de région constante d'IgG est choisi dans l'ensemble formé par un gène de région constante d'IgG1, un gène de région constante d'IgG2b et un gène de région constante d'IgG2a, ainsi que les combinaisons de tels gènes.

3. Souris conforme à la revendication 2, dans laquelle le gène de région constante d'IgG est un gène de région constante d'IgG1.

4. Souris conforme à la revendication 3, **caractérisée en ce que** cette souris exprime en plus :

- a) une protéine IgG3 de type sauvage,
- b) une protéine IgG2a de type sauvage,
- c) et une protéine IgG2b de type sauvage.

5. Souris conforme à la revendication 4, **caractérisée en outre en ce que** cette souris exprime :

- a) une protéine IgM de type sauvage,
- b) une protéine IgD de type sauvage,
- c) une protéine IgA de type sauvage,
- d) et une protéine IgE de type sauvage.

6. Souris conforme à la revendication 1, **caractérisée en ce qu'il** manque, à l'anticorps chaîne lourde d'IgG, (a) tout ou (b) partie du domaine CH1.

7. Souris conforme à la revendication 1, dans laquelle l'anticorps chaîne lourde d'IgG comprend le domaine variable humain, une charnière d'IgG1, un domaine CH2 et un domaine CH3.

8. Souris conforme à la revendication 1, laquelle souris comporte un locus fonctionnel de gène de chaîne légère d'immunoglobuline.

9. Souris conforme à la revendication 8, dans laquelle le locus de gène de chaîne légère d'immunoglobuline est un locus de gène de chaîne légère κ .

10. Souris conforme à la revendication 8, dans laquelle le locus de gène de chaîne légère d'immunoglobuline est un locus de gène de chaîne légère λ .

11. Souris conforme à la revendication 1, laquelle souris provient d'une souche choisie dans l'ensemble formé par une souche 129, une souche C57BL/6, et une souche mixte 129xC57BL/6.

12. Souris conforme à la revendication 11, laquelle souris est à 50% 129 et à 50% C57BL/6.

13. Cellule isolée de souris, laquelle cellule comporte une modification comprenant :

- 5 a) la délétion d'une séquence d'acide nucléique, codant un domaine CH1, d'un gène de région constante d'IgG endogène ;
b) et l'inclusion d'un ou de plusieurs segment(s) de gène humain de région variable de chaîne lourde, lequel ou lesquels segment(s) de gène humain de région variable de chaîne lourde est ou sont opérationnellement
10 raccordé(s) au reste du gène de région constante d'IgG endogène de l'item (a) ;

étant entendu que la cellule comporte un gène intact de région constante d'IgM, que la cellule exprime un anticorps chaîne lourde d'IgG qui comporte un domaine variable humain, n'a pas de domaine CH1 fonctionnel et n'est pas accompagné d'une chaîne légère, et que la cellule sécrète ledit anticorps chaîne lourde d'IgG.

15 14. Cellule souche embryonnaire (CSE) de souris, qui comporte une modification comprenant :

- a) la délétion d'une séquence d'acide nucléique, codant un domaine CH1, d'un gène de région constante d'IgG endogène ;
b) et l'inclusion d'un ou de plusieurs segment(s) de gène humain de région variable de chaîne lourde, lequel
20 ou lesquels segment(s) de gène humain de région variable de chaîne lourde est ou sont opérationnellement raccordé(s) au reste du gène de région constante d'IgG endogène de l'item (a) ;

étant entendu que la cellule CSE comporte un gène intact de région constante d'IgM, et que la cellule CSE peut donner naissance à une souris exprimant un anticorps chaîne lourde d'IgG qui comporte un domaine variable
25 humain, n'a pas de domaine CH1 fonctionnel et n'est pas accompagné d'une chaîne légère, laquelle souris sécrète ledit anticorps chaîne lourde d'IgG dans son sérum.

30

35

40

45

50

55




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11

	FR1	CDR1	FR2	CDR2	
B1	EVQLQQSGAELVRPGSSVKMSCKTS	GYTFTSYG.	INWVKQRPGQGLEWIGY	IYIGNGYT..	EYNEKFK
B2	EVQLQQSGrELVKPGASVmISctAS	GYTFiDYf.	iNWmKrSHGqSLEWIGD	INPNNGGs..	nYNQKFK
B3	QVQLQQPGAELVKPGASVKLSCKAS	GYTFTSYW.	MQWVKQRPGQGLEWIGE	IDPDSYt..	NYNQKFK
B5	EVQLQQSGAEiVKsGASVKLSCTAS	GFNmKDYf.	iHWVKQRTEQGLEWIGR	lDPEDGkT..	KYAPKFQ
D2	DVQLQESGPGLVKPSQSLSLTCSVT	GYSITSGYY	WNWIRQFPGNKLEWMGY	ISYDGrN...	NYNPSLK
D5	EVQLQQSGAELVRPGASVKLSCTAS	GFNIKDYY.	iHWVKkrPEQGLEWIGR	IDPEDGDT..	EYAPKFQ
D6	EVQLQQSGTELVKPGASaKLSCtAS	GFNVKDYf.	MHWVKQkTEQGLEWIGR	IVPEDGET..	KsAPKFQ
E2	EVKLVEsGGGLVQSGRSLRLSCATS	GFTFSDFY.	MEWVRQAPGKLEWIAt	SRNKlNDYTp	EfsASVK
E8	QVQLQQPGAELVKPGASVKLSCKAS	GYTFTSYW.	MHWVKQRPGRGLEWIGR	IDPNsGGT..	KYNEKlK
E10	EVQLQQSGPELVKPGASVKISCKAS	GYSFTGYY.	MNWVKQSPEKSLEWIGE	INPSTGGT..	TYNQKFK
F6	EVQLVESGGDLVePGGSLKLSCAAS	GFTFSsYG.	MSWVRQTPDKRLEWVAT	ISSGGsYT..	YYPDSVK

	FR3	CDR3	FR4	CH2	
B1	GKATLTSDTSSSTAYMQLSSLTSEDSAIYFr	ARGrVGPY.....YFDY	WGQGTTTLTVSS	VPEVSSVFI	
B2	GKATLTVDKSSSTAYMdLRSLTSEDSAVYYC	AKLGRD.....WYFDV	WGtGTTVTVSS	VPEVSSVFI	
B3	GKATLTVDTSSSTAYMQLSSLTpEDSAVYYC	ARCRY.....YFDY	WGQGTTTLTVSS	VPEVSSVFI	
B5	GKATITADTSSNTAYLhLSSLTSEDtAVYYC	ARGGLGREE..YYAvDY	WGQGTSVTVSS	VPEVSSVFI	
D2	NRISITRDTSKNQFFLKLNSVTTEDTATYYC	AIHTVVGd....YvMDY	WGQGTSVTVSS	VPEVSSVFI	
D5	GKATMTADTSSNTAYLQlSSLTSEDiAVYYC	TTSRpF.....YFDY	WGQGTTTLTVSS	VPEVSSVFI	
D6	drtTirtDTSSNTshLQlnSLTSEDtAVYYC	ARNPP.....Y	WGQGLTVTVSv	VPEVSSVFI	
E2	GRFIVSRDTSQnILYLQMNALRpEDTAIYYC	ARAcSdYDR..YYAMdY	WGQGTSVTVSS	VPEVSSVFI	
E8	nKATLTVDKPSSTAYMQLSSLTSEDSAVYYC	AREEINYYGSTYgAMdY	WGQGTSVTVSS	VPEVSSVFI	
E10	AKATLTVDKSSSTAYMQLKSLTSEDSAVYYC	AGG.....YWYFDV	WGtGTTVTVSS	VPEVSSVFI	
F6	GRFTISRDNakNTLYLQmSSLKSEdTAMYYC	ARHDYYGSSYG.WYFDV	WGtGTTVTVSS	VPEVSSVFI	

Figure 12

	<u>FR1</u>	<u>CDR1</u>	<u>FR2</u>	<u>CDR2</u>	
A8	QVQLVQSGAEVKKPGASVKVSCKAS	GYTFTSYD.	INWVRQATGQGLEWMGW	MNPNSGkT..	GYAQKFQ
C2	QVQLVQSGAE m KKPGASVKVSCKAS	GYTFTSYG.	ISWVRQAPGQGLEWMGW	ISAYNGNT..	yYAQnLQ
D9	QVQLVQSGAE m KKPGASVKVSCKAS	GYTFTSYG.	ISWVRQAPGQGLEWMGW	ISAYNGNT..	yYAQnLQ
C4	QVQLVQSGAEVKKPGASVKVSCKAS	GYTFTSYG.	ISWVRQAPGQGLEWMGW	ISAYNGNT..	NYAQKLQ
H8	QVQLIQSGAEVKKPGASVKVSyKAS	dYTFTSYG.	ISWVRQAPGQGLEWMGW	ISAYNGNT..	NYAQnLQ
A5	QVQLVQSGAEVKKPGSSVKVSCKAS	GGTFSSYA.	ISWVRQAPGQGLEWMGG	IIPIFGTA..	NYAQKFQ
A2	QVQLVQSGAEVKKPGSSVKVSCKAS	GGTFSSYA.	ISWVRQAPGQGLEWMGG	IIPIFGTA..	NYAQKFQ
	<u>FR3</u>	<u>CDR3</u>	<u>FR4</u>	<u>HINGE</u>	
A8	GRVamTRkTSISTAYMELSSLRSED T AVYYC	AReDYSNYgd.....	FDY	WGQGT L VTVSS	VPRDCGC
C2	GRVTMTTDTSTSaAfMdLRSLRSDD T AVYYC	ARdgYStSSl.....	DY	WGQGT L VTVSS	VPRDCGC
D9	GRVTMTTDTSTSaAfMdLRSLRSDD T AVYYC	ARdgYStSSl.....	DY	WGQGT L VTVSS	VPRDCGC
C4	GRVTMTTDTSTSTAYMELRSLRSDD T AVYYC	ARddMITFGGVianYYYYGMDV		WGQGT T VTVtS	VPRDCGC
H8	GRVTMTTDTSTSTAYMELRSLRSDDsAVYYC	AReeLEl.....	FDY	WGQGT L VTVSS	VPRDCGC
A5	GRVTITTDESTSTAYMELSSLRSED T AVYYC	ARdgYStSSl.....	DY	WGQGT L VTVSS	VPRDCGC
A2	GRVTITTDESTSTAYMELSSLRSED T AVYYC	AvIAVAGT.....	YYYYGMDV	WGQGT T VTVS l	VPRDCGC

Figure 13

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5565332 A, Hoogenboom [0117]
- US 5639641 A, Pedersen [0117]
- US 5766886 A, Studnicka [0117]
- US 5859205 A, Adair [0117]
- US 6054297 A, Carter [0117]
- US 6407213 B, Carter [0117]
- US 6639055 B, Carter [0117]
- US 6849425 B, Huse [0117]
- US 6881557 B, Foote [0117]
- US 7098006 B, Gorman [0117]
- US 7175996 B, Watkins [0117]
- US 7235643 B, Nicolaides [0117]
- US 7393648 B, Rother [0117]
- US 7462697 B, Couto [0117]
- US 6586251 B [0135] [0138]
- US 7294754 B [0146] [0148]
- WO 2009114400 A [0147] [0149]
- WO 61285250 A [0165]

Non-patent literature cited in the description

- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. 1989 [0111]
- **AUSUBEL et al.** Short Protocols in Molecular Biology. Wiley & Sons, 1995 [0111]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. National Institutes of Health, 1987 [0111]
- **CHOTHIA ; LESK.** *J. Mol Biol.*, 1987, vol. 196, 901-917 [0111]
- **MANIATIS et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, 1982 [0128]
- **HUTCHINSON et al.** Mutagenesis at a specific position in a DNA sequence. *J. Biol. Chem.*, 1978, vol. 253 (18), 6551-60 [0130]
- **VALENZUELA et al.** High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. *Nature Biotech.*, 2003, vol. 21 (6), 652-659 [0135] [0138]
- **POUEYMIROU et al.** F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses. *Nature Biotech.*, 2007, vol. 25 (1), 91-99 [0146] [0148]

**NEHÉZLÁNCÚ ANTITESTEKET TERMELŐ EGEREK
SZABADALMI IGÉNYPONTOK**

1. Transzgenikus egér, amely csíravonal módosításai rendelkezik, és amely módosítás magában foglalja:
 - (a) egy endogén IgG konstans régió gén CH1 doménját kódoló nukleinsav szekvencia delécióját; és
 - (b) egy vagy több emberi nehézlánc variábilis régió génszegmentek inklúzióját, ahol az egy vagy több emberi nehézlánc variábilis régió műteti úton kapcsolt az (a) endogén IgG konstans régióhoz;ahol az egér tartalmaz egy érintetlen IgM konstans régió gént, ahol az egér egy IgG nehézlánc antitestet exprimál, amely tartalmaz egy emberi variábilis domént, amelyből hiányzik egy funkcionális CH1 domén és amelyből hiányzik egy közös származású könnyűlánc, és ahol az egér az említett IgG nehézlánc antitestet szekretálja a vérérvájába.
2. Az egér az 1-es igénypont szerint, ahol az IgG konstans régió gén IgG1 konstans régió gént, IgG2b konstans régió gént, IgG2a konstans régió gént, vagy azok kombinációját tartalmazó csoportból kiválasztott.
3. Az egér a 2-es igénypont szerint, ahol az IgG konstans régió gén egy IgG1 konstans régió gén.
4. Az egér a 3-as igénypont szerint, azzal jellemezve, hogy az egér exprimál továbbá:
 - (a) vad típusú IgG3 fehérjét;
 - (b) vad típusú IgG2a fehérjét; és
 - (c) vad típusú IgG2b fehérjét.
5. Az egér a 4-es igénypont szerint, azzal jellemezve, hogy az egér exprimál:
 - (a) vad típusú IgM fehérjét;
 - (b) vad típusú IgD fehérjét;
 - (c) vad típusú IgA fehérjét; és
 - (d) vad típusú IgE fehérjét.
6. Az egér az 1-es igénypont szerint, azzal jellemezve, hogy az IgG nehézlánc antitestből hiányzik a CH1 domén: (a) teljes mértékben; vagy (b) részben.
7. Az egér az 1-es igénypont szerint, ahol az IgG nehézlánc antitest tartalmazza az emberi variábilis domént, továbbá egy IgG1 kapocs régiót, egy CH2 domént, és egy CH3 domént.
8. Az egér az 1-es igénypont szerint, ahol az egér rendelkezik egy funkcionális immunoglobulin könnyűlánc génlókusssal.
9. Az egér a 8-as igénypont szerint, ahol az immunoglobulin könnyűlánc génlókus egy κ könnyűlánc génlókus.
10. Az egér a 8-as igénypont szerint, ahol az immunoglobulin könnyűlánc génlókus egy λ könnyűlánc génlókus.

11. Az egér az 1-es igénypont szerint, ahol az egér 129-es törzset, C57BL/6 törzset, és egy kevert 129xC57BL/6 törzset tartalmazó csoportból választott törzsből származik.

12. Az egér a 11-es igénypont szerint, ahol egér 50%-ban 129-es törzsű és 50%-ban C57BL/6 törzsű.

13. Izolált egér sejt, ahol a sejt rendelkezik egy módosítással, amely magában foglalja:

(a) egy endogén IgG konstans régió gén CH1 doménjét kódoló nukleinsav szekvencia delécióját; és

(b) egy vagy több emberi nehézlánc variábilis régió génszegmens inkluzióját, ahol az egy vagy több emberi nehézlánc variábilis régió műtéti úton kapcsolt az (a) endogén IgG konstans régiójához;

ahol a sejt tartalmaz egy érintetlen IgM konstans régió gént, ahol a sejt egy IgG nehézlánc antitestet exprimál, amely tartalmaz egy emberi variábilis domént, amelyből hiányzik egy funkcionális CH1 domén és amelyből hiányzik egy közös származású könnyűlánc, és ahol a sejt az említett IgG nehézlánc antitestet szekretálja.

14. Egér embrionális őssejt (ES), amely rendelkezik egy módosítással, amely magában foglalja:

(a) egy endogén IgG konstans régió gén CH1 doménjét kódoló nukleinsav szekvencia delécióját; és

(b) egy vagy több emberi nehézlánc variábilis régió génszegmens inkluzióját, ahol az egy vagy több emberi nehézlánc variábilis régió műtéti úton kapcsolt az (a) endogén IgG konstans régiójához;

ahol az embrionális őssejt (ES) tartalmaz egy érintetlen IgM konstans régió gént, ahol az embrionális őssejt (ES) előidézheti az egér egy IgG nehézlánc antitest exprimálását, amely tartalmaz egy emberi variábilis domént, amelyből hiányzik egy funkcionális CH1 domén és amelyből hiányzik egy közös származású könnyűlánc, és ahol az egér az említett IgG nehézlánc antitestet szekretálja a vérsavójába.